1
|
Rojas JI, Gracia F, Parciak T, Alonso R, Becker J, Treviño-Frenk I, Alonso-Serena M, Giunta D, Abad P, Carnero-Contentti E, Carrá A, Correa-Díaz EP, Correale J, Cristiano E, Flores J, Fruns M, Galleguillos L, Garcea O, Hamuy F, Lana-Peixoto M, Navas C, Pappais-Alvarenga R, Patrucco L, Rivera V, Tenembaum S, Ysrraelit MC, Peeters LM. [Core data set for real world data in multiple sclerosis: customization for latin america from a global task force recommendation]. Rev Neurol 2024; 78:185-197. [PMID: 38502167 DOI: 10.33588/rn.7807.2023326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/20/2024]
Abstract
INTRODUCTION The primary objective of the core data set is to reduce heterogeneity and promote harmonization among data sources in EM, thereby reducing the time needed to execute real life data collection efforts. Recently, a group led by the Multiple Sclerosis Data Alliance has developed a core data set for collecting real-world data on multiple sclerosis (MS) globally. Our objective was to adapt this global data set to the needs of Latin America, so that it can be implemented by the registries already developed and in the process of development in the region. MATERIAL AND METHODS A working group was formed regionally, the core data set created globally was adapted (translation process into Spanish, incorporation of regional variables and consensus on variables to be used). Consensus was obtained through the remote Delphi methodology of a round of questionnaires and remote discussion of the core data set variables. RESULTS A total of 25 professionals from Latin America carried out the adaptation process between November 2022 and July 2023. Agreement was established on a core data set of nine categories and 45 variables, version 2023 to suggest its implementation in developed or developing registries, and MS cohorts in the region. CONCLUSION The core data set seeks to harmonize the variables collected by registries and cohorts in MS in Latin America in order to facilitate said collection and allow collaboration between sources. Its implementation will facilitate real life data collection and collaboration in the region.
Collapse
Affiliation(s)
- J I Rojas
- Hospital Alemán, Buenos Aires, Argentina
- Centro de Esclerosis Múltiple de Buenos Aires (CEMBA), Buenos Aires, Argentina
| | - F Gracia
- Hospital Santo Tomás, Panamá, República de Panamá
| | - T Parciak
- Universidad Hasselt, Diepenbeek, Bélgica
| | - R Alonso
- Hospital J. M. Ramos Mejía, Buenos Aires, Argentina
- Universidad de Buenos Aires, Buenos Aires, Argentina
- Sanatorio Güemes, Buenos Aires, Argentina
| | - J Becker
- Universidad Pontificia de Rio Grande do Sul, Porto Alegre, Brasil
| | - I Treviño-Frenk
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México
| | | | - D Giunta
- Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - P Abad
- Hospital Metropolitano de Quito, Quito, Ecuador
| | | | - A Carrá
- Hospital Británico, Buenos Aires, Argentina
- Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina
| | - E P Correa-Díaz
- Hospital Carlos Andrade Marín. Universidad Central del Ecuador, Quito, Ecuador
| | | | - E Cristiano
- Centro de Esclerosis Múltiple de Buenos Aires (CEMBA), Buenos Aires, Argentina
| | - J Flores
- Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México
| | - M Fruns
- Clínica Las Condes , Santiago de Chile, Chile
| | - L Galleguillos
- Clinica Alemana, Santiago de Chile, Chile
- Universidad del Desarrollo, Santiago de Chile, Chile
| | - O Garcea
- Hospital J. M. Ramos Mejía, Buenos Aires, Argentina
- Universidad de Buenos Aires, Buenos Aires, Argentina
| | - F Hamuy
- Hospital IMT, Asunción, Paraguay
| | - M Lana-Peixoto
- Universidad Federal de Minas Gerais, Belo Horizonte, Brasil
| | - C Navas
- Clínica Universitaria Colombia, Bogotá, Colombia
| | | | - L Patrucco
- Centro de Esclerosis Múltiple de Buenos Aires (CEMBA), Buenos Aires, Argentina
| | - V Rivera
- Universidad de Medicina Baylor, Houston, EE.UU
| | - S Tenembaum
- Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina
| | | | | |
Collapse
|
2
|
Dornburg A, Zapfe KL, Williams R, Alfaro ME, Morris R, Adachi H, Flores J, Santini F, Near TJ, Frédérich B. Considering decoupled phenotypic diversification between ontogenetic phases in macroevolution: An example using Triggerfishes (Balistidae). Syst Biol 2024:syae014. [PMID: 38490727 DOI: 10.1093/sysbio/syae014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Indexed: 03/17/2024] Open
Abstract
Across the Tree of Life, most studies of phenotypic disparity and diversification have been restricted to adult organisms. However, many lineages have distinct ontogenetic phases that differ from their adult forms in morphology and ecology. Focusing disproportionately on the evolution of adult forms unnecessarily hinders our understanding of the pressures shaping evolution over time. Non-adult disparity patterns are particularly important to consider for coastal ray-finned fishes, which often have juvenile phases with distinct phenotypes. These juvenile forms are often associated with sheltered nursery environments, with phenotypic shifts between adults and juvenile stages that are readily apparent in locomotor morphology. Whether this ontogenetic variation in locomotor morphology reflects a decoupling of diversification dynamics between life stages remains unknown. Here we investigate the evolutionary dynamics of locomotor morphology between adult and juvenile triggerfishes. We integrate a time-calibrated phylogenetic framework with geometric morphometric approaches and measurement data of fin aspect ratio and incidence, and reveal a mismatch between morphospace occupancy, the evolution of morphological disparity, and the tempo of trait evolution between life stages. Collectively, our results illuminate how the heterogeneity of morpho-functional adaptations can decouple the mode and tempo of morphological diversification between ontogenetic stages.
Collapse
Affiliation(s)
- Alex Dornburg
- University of North Carolina at Charlotte, Charlotte, NC, USA
| | | | | | - Michael E Alfaro
- Department of Ecology and Evolutionary Biology, University of California, Los Angeles, CA, USA
| | - Richard Morris
- North Carolina Museum of Natural Sciences, Raleigh, NC, USA
| | - Haruka Adachi
- North Carolina Museum of Natural Sciences, Raleigh, NC, USA
| | - Joseph Flores
- North Carolina Museum of Natural Sciences, Raleigh, NC, USA
| | - Francesco Santini
- Associazione Italiana per lo Studio della Biodiversità, Pisa, 56100, Italy
| | - Thomas J Near
- Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, USA
| | - Bruno Frédérich
- Laboratory of Evolutionary Ecology, FOCUS, University of Liège, Liège, Belgium
| |
Collapse
|
3
|
Siegel P, Richardson M, Flores J, Poole JL. Retrospective chart review suggests patients referred to therapy following digit and partial thumb amputations have decreased pain and improved function. J Hand Ther 2023; 36:770-772. [PMID: 37596150 DOI: 10.1016/j.jht.2023.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 02/01/2023] [Accepted: 02/07/2023] [Indexed: 08/20/2023]
Affiliation(s)
- Patricia Siegel
- Occupational Therapy Graduate Program, University of New Mexico, Albuquerque, New Mexico.
| | - Maxwell Richardson
- Occupational Therapy Graduate Program, University of New Mexico, Albuquerque, New Mexico
| | - Joseph Flores
- University of New Mexico Hospital, Albuquerque, New Mexico
| | - Janet L Poole
- Occupational Therapy Graduate Program, University of New Mexico, Albuquerque, New Mexico
| |
Collapse
|
4
|
Flores J, Ziegler B, Silvello D, Dalcin P. Effects of an early rehabilitation program for adult cystic fibrosis patients during hospitalization: a randomized clinical trial. Braz J Med Biol Res 2023; 56:e12752. [PMID: 37585917 PMCID: PMC10427163 DOI: 10.1590/1414-431x2023e12752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Accepted: 06/14/2023] [Indexed: 08/18/2023] Open
Abstract
There is little information on pulmonary rehabilitation in patients with cystic fibrosis (CF) with pulmonary exacerbation. This study aimed to evaluate the effects of an early rehabilitation program on lung function, muscle strength, inflammatory markers, and quality of life in adults with CF hospitalized for pulmonary exacerbation. In this randomized controlled trial, 19 patients were included in the intervention group and 15 in the control group. The intervention group underwent an early rehabilitation program for 14 days after admission. All patients underwent spirometry, one-repetition maximum tests (1RM), and the 6-min walk test, and answered the Revised Cystic Fibrosis Questionnaire (CFQ-R) for quality of life and the International Physical Activity Questionnaire. Serum levels of interleukin and tumor necrosis factor alpha (TNF-α) were measured. In the intervention group, there were increases in 1RM biceps (P=0.009), triceps (P=0.005), shoulder abductors (P=0.002), shoulder flexors (P=0.004), hamstrings (P<0.001), and quadriceps values (P<0.001). In addition, there were improvements in CFQ-R-emotion (P=0.002), treatment burden (P=0.002), vitality (P=0.011), and physical scores (P=0.026), and a reduction in the Borg resting fatigue score (P=0.037). The interleukins levels did not change after the intervention. In adult CF patients with pulmonary exacerbation, early hospital rehabilitation had a significant impact on improving resting fatigue, muscle strength, and quality of life.
Collapse
Affiliation(s)
- J. Flores
- Programa de Pós-Graduação em Ciências Pneumológicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil
| | - B. Ziegler
- Hospital de Clínicas de Porto Alegre, Serviço de Pneumologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil
| | - D. Silvello
- Programa de Pós-Graduação em Ciências Pneumológicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil
| | - P.T.R. Dalcin
- Programa de Pós-Graduação em Ciências Pneumológicas, Hospital de Clínicas de Porto Alegre, Serviço de Pneumologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil
| |
Collapse
|
5
|
Vandegrift R, Newman DS, Dentinger BTM, Batallas-Molina R, Dueñas N, Flores J, Goyes P, Jenkinson TS, McAlpine J, Navas D, Policha T, Thomas DC, Roy BA. Richer than Gold: the fungal biodiversity of Reserva Los Cedros, a threatened Andean cloud forest. Bot Stud 2023; 64:17. [PMID: 37410314 DOI: 10.1186/s40529-023-00390-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Accepted: 06/08/2023] [Indexed: 07/07/2023]
Abstract
BACKGROUND Globally, many undescribed fungal taxa reside in the hyperdiverse, yet undersampled, tropics. These species are under increasing threat from habitat destruction by expanding extractive industry, in addition to global climate change and other threats. Reserva Los Cedros is a primary cloud forest reserve of ~ 5256 ha, and is among the last unlogged watersheds on the western slope of the Ecuadorian Andes. No major fungal survey has been done there, presenting an opportunity to document fungi in primary forest in an underrepresented habitat and location. Above-ground surveys from 2008 to 2019 resulted in 1760 vouchered collections, cataloged and deposited at QCNE in Ecuador, mostly Agaricales sensu lato and Xylariales. We document diversity using a combination of ITS barcode sequencing and digital photography, and share the information via public repositories (GenBank & iNaturalist). RESULTS Preliminary identifications indicate the presence of at least 727 unique fungal species within the Reserve, representing 4 phyla, 17 classes, 40 orders, 101 families, and 229 genera. Two taxa at Los Cedros have recently been recommended to the IUCN Fungal Red List Initiative (Thamnomyces chocöensis Læssøe and "Lactocollybia" aurantiaca Singer), and we add occurrence data for two others already under consideration (Hygrocybe aphylla Læssøe & Boertm. and Lamelloporus americanus Ryvarden). CONCLUSIONS Plants and animals are known to exhibit exceptionally high diversity and endemism in the Chocó bioregion, as the fungi do as well. Our collections contribute to understanding this important driver of biodiversity in the Neotropics, as well as illustrating the importance and utility of such data to conservation efforts. RESUMEN Antecedentes: A nivel mundial muchos taxones fúngicos no descritos residen en los trópicos hiper diversos aunque continúan submuestreados. Estas especies están cada vez más amenazadas por la destrucción del hábitat debido a la expansión de la industria extractivista además del cambio climático global y otras amenazas. Los Cedros es una reserva de bosque nublado primario de ~ 5256 ha y se encuentra entre las últimas cuencas hidrográficas no explotadas en la vertiente occidental de los Andes ecuatorianos. Nunca antes se ha realizado un estudio de diversidad micológica en el sitio, lo que significa una oportunidad para documentar hongos en el bosque primario, en hábitat y ubicación subrepresentatadas. El presente estudio recopila información entre el 2008 y 2019 muestreando material sobre todos los sustratos, reportando 1760 colecciones catalogadas y depositadas en el Fungario del QCNE de Ecuador, en su mayoría Agaricales sensu lato y Xylariales; además se documenta la diversidad mediante secuenciación de códigos de barras ITS y fotografía digital, la información está disponible en repositorios públicos digitales (GenBank e iNaturalist). RESULTADOS La identificación preliminar indica la presencia de al menos 727 especies únicas de hongos dentro de la Reserva, que representan 4 filos, 17 clases, 40 órdenes, 101 familias y 229 géneros. Recientemente dos taxones en Los Cedros se recomendaron a la Iniciativa de Lista Roja de Hongos de la UICN (Thamnomyces chocöensis Læssøe y "Lactocollybia" aurantiaca Singer) y agregamos datos de presencia de otros dos que ya estaban bajo consideración (Hygrocybe aphylla Læssøe & Boertm. y Lamelloporus americanus Ryvarden). CONCLUSIONES Se sabe que plantas y animales exhiben una diversidad y endemismo excepcionalmente altos en la bioregión del Chocó y los hongos no son la excepción. Nuestras colecciones contribuyen a comprender este importante promotor de la biodiversidad en el Neotrópico además de ilustrar la importancia y utilidad de dichos datos para los esfuerzos de conservación.
Collapse
Affiliation(s)
- R Vandegrift
- Inst. of Ecology and Evolution, Department of Biology, University of Oregon, Eugene, OR, 97402, USA.
- Herbario Nacional del Ecuador (QCNE), sección botánica del Instituto Nacional de Biodiversidad (INABIO), Avenida Río Coca E6-115 e Isla Fernandina, Sector Jipijapa, Quito, Ecuador.
| | - D S Newman
- , Glorieta, NM, USA
- Herbario Nacional del Ecuador (QCNE), sección botánica del Instituto Nacional de Biodiversidad (INABIO), Avenida Río Coca E6-115 e Isla Fernandina, Sector Jipijapa, Quito, Ecuador
| | - B T M Dentinger
- Biology Department and Natural History Museum, University of Utah, Salt Lake City, Utah, USA
| | - R Batallas-Molina
- Herbario Nacional del Ecuador (QCNE), sección botánica del Instituto Nacional de Biodiversidad (INABIO), Avenida Río Coca E6-115 e Isla Fernandina, Sector Jipijapa, Quito, Ecuador
| | - N Dueñas
- Departamento de Investigación de Mycomaker, Quito, Ecuador
| | - J Flores
- Departamento de Investigación de Reino Fungi, Quito, Ecuador
| | - P Goyes
- Microbiology Institute-Universidad San Francisco de Quito, Quito, Ecuador
| | - T S Jenkinson
- Department of Biological Sciences, California State University, East Bay, Hayward, CA, USA
| | - J McAlpine
- Inst. of Ecology and Evolution, Department of Biology, University of Oregon, Eugene, OR, 97402, USA
| | - D Navas
- Herbario Nacional del Ecuador (QCNE), sección botánica del Instituto Nacional de Biodiversidad (INABIO), Avenida Río Coca E6-115 e Isla Fernandina, Sector Jipijapa, Quito, Ecuador
| | - T Policha
- Inst. of Ecology and Evolution, Department of Biology, University of Oregon, Eugene, OR, 97402, USA
| | - D C Thomas
- Inst. of Ecology and Evolution, Department of Biology, University of Oregon, Eugene, OR, 97402, USA
- Bayreuth Center of Ecology and Research, University of Bayreuth, Bayreuth, Bayern, DE, Germany
| | - B A Roy
- Inst. of Ecology and Evolution, Department of Biology, University of Oregon, Eugene, OR, 97402, USA
| |
Collapse
|
6
|
Mendoza K, Aliquó GA, Prieto JA, Torres MR, Blas R, Flores J, Casas A. Prospection and identification of backcrossings of traditional-heritage peruvian grapevine cultivars (Vitis vinifera L.) from Ica and Cañete Valleys. BIO Web Conf 2023. [DOI: 10.1051/bioconf/20235601004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2023] Open
Abstract
La vid (Vitis vinifera L.) fue introducida en Sudamérica durante el siglo XVI. En los valles de Ica y Cañete, los nombres "Quebranta Mollar", "Mollar" y "Prieta Mollar" son comúnmente utilizados en referencia a los diferentes colores de las bayas de estas variedades dentro de un mismo racimo. Esta heterogeneidad en cuanto al color de las bayas, sumada a los antecedentes históricos, sugieren que otras variedades, además de Quebranta y Mollar Cano, podrían estar implicadas en esta denominación genérica "Mollar". En este trabajo se identificaron diferentes fenotipos correspondientes a algunas variedades utilizadas en la elaboración de vino y Pisco. Para ello, 10 accesiones fueron recolectadas en 9 viñedos diferentes (valles de Ica y Cañete), y analizadas utilizando 20 marcadores moleculares y 25 descriptores morfológicos según la OIV. Nuestros resultados mostraron que las muestras recolectadas correspondieron a 5 genotipos, tres cultivares tradicionales y dos genotipos desconocidos no registrados previamente. Los tres cultivares conocidos fueron Listan Prieto, Quebranta y Mollar Cano. Las dos accesiones correspondientes a variedades no conocidas previamente fueron Mollar de Ica y Prieta Mollar, generadas a partir de retrocruzamientos entre Quebranta y sus progenitores. También se identificaron diferentes variaciones fenotípicas de Quebranta, lo cual enriquece la diversidad vitícola peruana.
Collapse
|
7
|
Siegel P, Richardson M, Flores J. Exploration of Outcomes and Interventions Used Following Digit Amputation. Arch Phys Med Rehabil 2022. [DOI: 10.1016/j.apmr.2022.08.855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
|
8
|
Flores J, Fillion ML, LeBlanc AC. Caspase-1 inhibition improves cognition without significantly altering amyloid and inflammation in aged Alzheimer disease mice. Cell Death Dis 2022; 13:864. [PMID: 36220815 PMCID: PMC9553979 DOI: 10.1038/s41419-022-05290-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 09/21/2022] [Accepted: 09/22/2022] [Indexed: 11/07/2022]
Abstract
Human genetic and animal model studies indicate that brain microglial inflammation is a primary driver of cognitive impairment in Alzheimer Disease (AD). Inflammasome-activated Caspase-1 (Casp1) is associated with both AD microglial inflammation and neuronal degeneration. In mice, Casp1 genetic ablation or VX-765 small molecule inhibition of Casp1 given at onset of cognitive deficits strongly supports the association between microglial inflammation and cognitive impairment. Here, VX-765 significantly improved episodic and spatial memory impairment eight months after the onset of cognitive impairment in aged AD mice with significant amyloid beta peptide (Aβ) accumulation and microglial inflammation. Unexpectedly, while cognitive improvement was associated with dendritic spine density and hippocampal synaptophysin level recovery, VX-765 only slightly decreased Aβ deposition and did not alter biochemically-measured Aβ levels. Furthermore, increased hippocampal Iba1+-microglia, GFAP+-astrocytes, IL-1β, and TNF-α levels were unaltered by VX-765. These results support the hypothesis that neuronal degeneration, not Aβ or microglial inflammation, drives cognitive impairment in AD.
Collapse
Affiliation(s)
- Joseph Flores
- grid.414980.00000 0000 9401 2774Lady Davis Institute for Medical Research at Jewish General Hospital, Montréal, QC Canada
| | - Marie-Lyne Fillion
- grid.414980.00000 0000 9401 2774Lady Davis Institute for Medical Research at Jewish General Hospital, Montréal, QC Canada
| | - Andréa C. LeBlanc
- grid.414980.00000 0000 9401 2774Lady Davis Institute for Medical Research at Jewish General Hospital, Montréal, QC Canada ,grid.14709.3b0000 0004 1936 8649Department of Neurology and Neurosurgery, McGill University, Montréal, QC Canada
| |
Collapse
|
9
|
Flores J, Moriarty A, Lizette F, Lang A, Rosenthal A, Papadopoulos K, Beeram M, Patnaik A, Rasco D, DeBerry B, Elmi M, Drengler R, Hernandez T, Sharma M, Lakhani N, Smith L, Moreno V, Calvo E, Garcia-Foncillas J, Wick M. Identification and molecular characterization of invasive lobular breast cancer models in a panel of 180 breast XPDX models. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01121-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
10
|
Flores J, Moreno C, Moriarty A, Papadopoulos K, Drengler R, Rodriguez L, Salih H, Rasco D, Patnaik A, Wick M. Establishment and characterization of HPV+ metastatic squamous cell anal carcinoma XPDX models in athymic nude mice. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00837-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
11
|
Moriarty A, Flores J, Stackpole A, Ulmer S, Papadopoulos K, Patnaik A, Rasco D, Calvo E, Moreno V, Wick M. Establishment and characterization of an EGFR-mutant NSCLC XPDX model representing first-line osimertinib resistance through an acquired TRIM24-BRAF fusion. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01097-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
12
|
Tortajada C, Navarro A, Andreu-Ballester JC, Mayor A, Añón S, Flores J. Prevalence and duration of symptoms among moderate and severe COVID-19 patients 12 months after discharge. Intern Emerg Med 2022; 17:929-934. [PMID: 35023003 PMCID: PMC8754532 DOI: 10.1007/s11739-021-02895-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Accepted: 11/15/2021] [Indexed: 11/28/2022]
Affiliation(s)
- C Tortajada
- Infectious Disease Unit, Internal Medicine Department, Hospital Arnau de Vilanova, San Clemente 12, 46015, Valencia, Spain.
| | - A Navarro
- Internal Medicine Department, Hospital Arnau de Vilanova, San Clemente 12, 46015, Valencia, Spain
| | - J C Andreu-Ballester
- Research Department, Hospital Arnau de Vilanova, San Clemente 12, 46015, Valencia, Spain
| | - A Mayor
- Internal Medicine Department, Hospital Arnau de Vilanova, San Clemente 12, 46015, Valencia, Spain
| | - S Añón
- Internal Medicine Department, Hospital Arnau de Vilanova, San Clemente 12, 46015, Valencia, Spain
| | - J Flores
- Infectious Disease Unit, Internal Medicine Department, Hospital Arnau de Vilanova, San Clemente 12, 46015, Valencia, Spain
| |
Collapse
|
13
|
Warren B, Henson L, Thomas H, Baclay J, Flores J, Tangco E, Patel S, Sanghvi P, Li B. Establishing Partnerships and Developing Relevant Virtual Curriculum to Augment Contouring Education in Southeast Asia. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Chilengi R, Mwila-Kazimbaya K, Chirwa M, Sukwa N, Chipeta C, Velu RM, Katanekwa N, Babji S, Kang G, McNeal MM, Meyer N, Gompana G, Hazra S, Tang Y, Flores J, Bhat N, Rathi N. Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants. Vaccine 2021; 39:3633-3640. [PMID: 33992437 PMCID: PMC8204902 DOI: 10.1016/j.vaccine.2021.04.060] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 03/17/2021] [Accepted: 04/28/2021] [Indexed: 02/03/2023]
Abstract
BACKGROUND AND AIMS ROTAVAC® (frozen formulation stored at -20 °C) and ROTAVAC 5D® (liquid formulation stable at 2-8 °C) are rotavirus vaccines derived from the 116E human neonatal rotavirus strain, developed and licensed in India. This study evaluated and compared the safety and immunogenicity of these vaccines in an infant population in Zambia. METHODS We conducted a phase 2b, open-label, randomized, controlled trial wherein 450 infants 6 to 8 weeks of age were randomized equally to receive three doses of ROTAVAC or ROTAVAC 5D, or two doses of ROTARIX®. Study vaccines were administered concomitantly with routine immunizations. Blood samples were collected pre-vaccination and 28 days after the last dose. Serum anti-rotavirus IgA antibodies were measured by ELISA, with WC3 and 89-12 rotavirus strains as viral lysates in the assays. The primary analysis was to assess non-inferiority of ROTAVAC 5D to ROTAVAC in terms of the geometric mean concentration (GMC) of serum IgA (WC3) antibodies. Seroresponse and seropositivity were also determined. Safety was evaluated as occurrence of immediate, solicited, unsolicited, and serious adverse events after each dose. RESULTS The study evaluated 388 infants in the per-protocol population. All three vaccines were well tolerated and immunogenic. The post-vaccination GMCs were 14.0 U/mL (95% CI: 10.4, 18.8) and 18.1 U/mL (95% CI: 13.7, 24.0) for the ROTAVAC and ROTAVAC 5D groups, respectively, yielding a ratio of 1.3 (95% CI: 0.9, 1.9), thus meeting the pre-set non-inferiority criteria. Solicited and unsolicited adverse events were similar across all study arms. No death or intussusception case was reported during study period. CONCLUSIONS Among Zambian infants, both ROTAVAC and ROTAVAC 5D were well tolerated and the immunogenicity of ROTAVAC 5D was non-inferior to that of ROTAVAC. These results are consistent with those observed in licensure trials in India and support use of these vaccines across wider geographical areas.
Collapse
Affiliation(s)
- R Chilengi
- Centre for Infectious Disease Research in Zambia, Zambia
| | | | - M Chirwa
- Centre for Infectious Disease Research in Zambia, Zambia
| | - N Sukwa
- Centre for Infectious Disease Research in Zambia, Zambia
| | - C Chipeta
- Centre for Infectious Disease Research in Zambia, Zambia
| | - R M Velu
- Centre for Infectious Disease Research in Zambia, Zambia
| | - N Katanekwa
- Centre for Infectious Disease Research in Zambia, Zambia
| | - S Babji
- The Wellcome Trust Research Laboratory, Vellore, India
| | - G Kang
- The Wellcome Trust Research Laboratory, Vellore, India
| | - M M McNeal
- Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - N Meyer
- Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | | | | | | | | | | | | |
Collapse
|
15
|
Flores J, Noël A, Foveau B, Beauchet O, LeBlanc AC. Publisher Correction: Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nat Commun 2021; 12:2271. [PMID: 33837216 PMCID: PMC8035171 DOI: 10.1038/s41467-021-22789-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-22789-7
Collapse
Affiliation(s)
- Joseph Flores
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.,Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
| | - Anastasia Noël
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.,Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
| | - Bénédicte Foveau
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| | - Olivier Beauchet
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.,Department of Medicine, Division of Geriatric Medicine, Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Quebec, Canada.,Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
| | - Andréa C LeBlanc
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. .,Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada. .,Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada.
| |
Collapse
|
16
|
De Los Reyes M, Palomino J, Araujo A, Flores J, Ramirez G, Parraguez VH, Aspee K. Cyclooxygenase 2 messenger RNA levels in canine follicular cells: interrelationship with GDF-9, BMP-15, and progesterone. Domest Anim Endocrinol 2021; 74:106529. [PMID: 32890884 DOI: 10.1016/j.domaniend.2020.106529] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2020] [Revised: 07/18/2020] [Accepted: 07/19/2020] [Indexed: 01/05/2023]
Abstract
Cyclooxygenase 2 (COX-2) encoded by the Cox-2 gene within the periovulatory follicles is a critical mediator of oocyte development. Growth differentiation factor 9 (GDF-9) and bone morphogenetic protein 15 (BMP-15) participate in the modulation of certain target genes in the ovary, possibly influencing the Cox-2 gene expression. However, this relationship has not been characterized in canines. This study aimed to examine the possible relationships among BMP-15, GDF-9, progesterone, and Cox-2 gene expression in granulosa-cumulus cells in dogs. Granulosa cells from antral follicles and their corresponding cumulus-oocyte complexes and follicular fluid (FF) were separately obtained from 56 ovaries collected from adult bitches at estrus (n = 15) and proestrus (n = 13) after ovariohysterectomy. Total RNA extraction was performed in follicular cells, and Cox-2 gene expression was assessed by quantitative PCR analysis. Progesterone, BMP-15, and GDF-9 were determined in the FF samples using ELISA assays. Cumulus-oocyte complexes were subjected to in vitro maturation (IVM) with or without (control) recombinant GDF-9 and BMP-15. After 72 h of culture, Cox-2 transcript analyses were performed in cumulus cells via quantitative PCR. Data were evaluated by ANOVA. An increase (P < 0.05) in Cox-2 messenger RNA levels was observed in follicular cells from follicles at estrus with respect to those at proestrus. However, the levels of BMP-15 and GDF-9 in FF decreased (P < 0.05), whereas progesterone increased (P < 0.05) from the proestrus phase to the estrus phase. The expression of Cox-2 gene in cumulus cells was 4-fold greater (P < 0.01) than that in the control when both growth factors were added to the IVM culture. In conclusion, although BMP-15 together with GDF-9 appears to upregulate the levels of Cox-2 transcripts during IVM, the inverse relationship of these paracrine factors with Cox-2 gene expression and the positive correlation of progesterone with Cox-2 transcripts suggest that the high progesterone levels could be more relevant in the local mechanisms regulating the Cox-2 gene expression.
Collapse
Affiliation(s)
- M De Los Reyes
- Laboratory of Animal Reproduction, Department of Animal Production, Faculty of Veterinary Sciences, University of Chile, Santa Rosa 11735, La Pintana, Santiago, Chile.
| | - J Palomino
- Laboratory of Animal Reproduction, Department of Animal Production, Faculty of Veterinary Sciences, University of Chile, Santa Rosa 11735, La Pintana, Santiago, Chile
| | - A Araujo
- Laboratory of Animal Reproduction, Department of Animal Production, Faculty of Veterinary Sciences, University of Chile, Santa Rosa 11735, La Pintana, Santiago, Chile
| | - J Flores
- Laboratory of Animal Reproduction, Department of Animal Production, Faculty of Veterinary Sciences, University of Chile, Santa Rosa 11735, La Pintana, Santiago, Chile
| | - G Ramirez
- Laboratory of Animal Reproduction, Department of Animal Production, Faculty of Veterinary Sciences, University of Chile, Santa Rosa 11735, La Pintana, Santiago, Chile
| | - V H Parraguez
- Laboratory of Animal Physiology, Department of Biological Sciences, Faculty of Veterinary Sciences, University of Chile, Santa Rosa, 11735, La Pintana, Santiago, Chile
| | - K Aspee
- Laboratory of Animal Reproduction, Department of Animal Production, Faculty of Veterinary Sciences, University of Chile, Santa Rosa 11735, La Pintana, Santiago, Chile
| |
Collapse
|
17
|
Flores J, Noël A, Foveau B, Beauchet O, LeBlanc AC. Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nat Commun 2020; 11:4571. [PMID: 32917871 PMCID: PMC7486940 DOI: 10.1038/s41467-020-18405-9] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Accepted: 08/20/2020] [Indexed: 02/07/2023] Open
Abstract
Early therapeutic interventions are essential to prevent Alzheimer Disease (AD). The association of several inflammation-related genetic markers with AD and the early activation of pro-inflammatory pathways in AD suggest inflammation as a plausible therapeutic target. Inflammatory Caspase-1 has a significant impact on AD-like pathophysiology and Caspase-1 inhibitor, VX-765, reverses cognitive deficits in AD mouse models. Here, a one-month pre-symptomatic treatment of Swedish/Indiana mutant amyloid precursor protein (APPSw/Ind) J20 and wild-type mice with VX-765 delays both APPSw/Ind- and age-induced episodic and spatial memory deficits. VX-765 delays inflammation without considerably affecting soluble and aggregated amyloid beta peptide (Aβ) levels. Episodic memory scores correlate negatively with microglial activation. These results suggest that Caspase-1-mediated inflammation occurs early in the disease and raise hope that VX-765, a previously Food and Drug Administration-approved drug for human CNS clinical trials, may be a useful drug to prevent the onset of cognitive deficits and brain inflammation in AD.
Collapse
Affiliation(s)
- Joseph Flores
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.,Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
| | - Anastasia Noël
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.,Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
| | - Bénédicte Foveau
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| | - Olivier Beauchet
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.,Department of Medicine, Division of Geriatric Medicine, Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Quebec, Canada.,Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
| | - Andréa C LeBlanc
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. .,Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada. .,Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada.
| |
Collapse
|
18
|
Wick M, Flores J, Moriarty A, Beeram M, Papadopoulos K. 54P Establishment and characterization of luminal A breast PDX models from patients with acquired resistance to CDK 4/6 inhibitors. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
19
|
Zhou L, Flores J, Noël A, Beauchet O, Sjöström PJ, LeBlanc AC. Methylene blue inhibits Caspase-6 activity, and reverses Caspase-6-induced cognitive impairment and neuroinflammation in aged mice. Acta Neuropathol Commun 2019; 7:210. [PMID: 31843022 PMCID: PMC6915996 DOI: 10.1186/s40478-019-0856-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Accepted: 11/25/2019] [Indexed: 12/20/2022] Open
Abstract
Activated Caspase-6 (Casp6) is associated with age-dependent cognitive impairment and Alzheimer disease (AD). Mice expressing human Caspase-6 in hippocampal CA1 neurons develop age-dependent cognitive deficits, neurodegeneration and neuroinflammation. This study assessed if methylene blue (MB), a phenothiazine that inhibits caspases, alters Caspase-6-induced neurodegeneration and cognitive impairment in mice. Aged cognitively impaired Casp6-overexpressing mice were treated with methylene blue in drinking water for 1 month. Methylene blue treatment did not alter Caspase-6 levels, assessed by RT-PCR, western blot and immunohistochemistry, but inhibited fluorescently-labelled Caspase-6 activity in acute brain slice intact neurons. Methylene blue treatment rescued Caspase-6-induced episodic and spatial memory deficits measured by novel object recognition and Barnes maze, respectively. Methylene blue improved synaptic function of hippocampal CA1 neurons since theta-burst long-term potentiation (LTP), measured by field excitatory postsynaptic potentials (fEPSPs) in acute brain slices, was successfully induced in the Schaffer collateral-CA1 pathway in methylene blue-treated, but not in vehicle-treated, Caspase-6 mice. Increased neuroinflammation, measured by ionized calcium binding adaptor molecule 1 (Iba1)-positive microglia numbers and subtypes, and glial fibrillary acidic protein (GFAP)-positive astrocytes, were decreased by methylene blue treatment. Therefore, methylene blue reverses Caspase-6-induced cognitive deficits by inhibiting Caspase-6, and Caspase-6-mediated neurodegeneration and neuroinflammation. Our results indicate that Caspase-6-mediated damage is reversible months after the onset of cognitive deficits and suggest that methylene blue could benefit Alzheimer disease patients by reversing Caspase-6-mediated cognitive decline.
Collapse
Affiliation(s)
- Libin Zhou
- Lady Davis Institute for Medical Research at Jewish General Hospital, 3999 Ch. Côte Ste-Catherine, Montreal, QC H3T 1E2 Canada
- Department of Anatomy and Cell Biology, McGill University, 3640 University Street Strathcona Anatomy Building, Montreal, QC H3A 0C7 Canada
| | - Joseph Flores
- Lady Davis Institute for Medical Research at Jewish General Hospital, 3999 Ch. Côte Ste-Catherine, Montreal, QC H3T 1E2 Canada
| | - Anastasia Noël
- Lady Davis Institute for Medical Research at Jewish General Hospital, 3999 Ch. Côte Ste-Catherine, Montreal, QC H3T 1E2 Canada
| | - Olivier Beauchet
- Lady Davis Institute for Medical Research at Jewish General Hospital, 3999 Ch. Côte Ste-Catherine, Montreal, QC H3T 1E2 Canada
- Department of Medicine, Division of Geriatric Medicine, Sir Mortimer B. Davis - Jewish General Hospital, 3999 Ch. Côte Ste-Catherine, Montreal, QC H3T 1E2 Canada
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
| | - P. Jesper Sjöström
- Centre for Research in Neuroscience, the BRaIN Program, Department of Neurology and Neurosurgery, McGill University, The Research Institute of the McGill University Health Centre, Montreal General Hospital, 1650 Cedar Avenue, Montreal, QC H3G 1A4 Canada
| | - Andrea C. LeBlanc
- Lady Davis Institute for Medical Research at Jewish General Hospital, 3999 Ch. Côte Ste-Catherine, Montreal, QC H3T 1E2 Canada
- Department of Anatomy and Cell Biology, McGill University, 3640 University Street Strathcona Anatomy Building, Montreal, QC H3A 0C7 Canada
- Department of Neurology and Neurosurgery, McGill University, 845 Sherbrooke O, Montreal, QC H3A 0G4 Canada
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, 3755 ch. Côte Ste-Catherine, Montréal, QC H3T 1E2 Canada
| |
Collapse
|
20
|
Ochoa-Morales A, Hernández-Mojica T, Paz-Rodríguez F, Jara-Prado A, Trujillo-De Los Santos Z, Sánchez-Guzmán MA, Guerrero-Camacho JL, Corona-Vázquez T, Flores J, Camacho-Molina A, Rivas-Alonso V, Dávila-Ortiz de Montellano DJ. Quality of life in patients with multiple sclerosis and its association with depressive symptoms and physical disability. Mult Scler Relat Disord 2019; 36:101386. [PMID: 31520986 DOI: 10.1016/j.msard.2019.101386] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 08/16/2019] [Accepted: 09/06/2019] [Indexed: 02/06/2023]
Abstract
OBJECTIVE The aim of this work was to evaluate the quality of life of patients with multiple sclerosis and its association with depressive symptoms and physical health. METHOD A total of 117 patients clinically diagnosed with Multiple Sclerosis (MS) were studied. The MSQOL-54 scale was applied. The depressive symptoms were assessed using the Beck Depression Inventory (BDI), while degree of physical disability was evaluated with the EDSS (Expanded Disability Status Scale). The results of these last two instruments were associated with MSQOL-54 to determine its influence on the perception of quality of life. RESULTS We evaluated 65 women (56%) and 52 men (44%), with a mean age of 35 years, a mean age of 27 years at the time of diagnosis, and a mean evolution of 8 years. 88% of the patients showed the relapsing-remitting subtype; 42% had paid employment; 29% of the studied patients required help to perform daily activities; 75% took disease-modifying medications. They obtained on average a score of 3.62 ± 2.30 on the EDSS and 11.5 ± 9.21 on the BDI. The general average in MSQOL-54 was 64.67 ± 17.52. CONCLUSIONS Quality of life, in patients with multiple sclerosis is an issue that worries health personnel, it is essential to implement strategies for reducing the impact of the disease on patients' lives, mainly through the application of programs aimed to decrees depression and improve social support.
Collapse
Affiliation(s)
- A Ochoa-Morales
- Department of Genetics, National Institute of Neurology and Neurosurgery MVS, Insurgentes Sur 3877 Col, La Fama, Tlalpan 14269 CDMX, Mexico
| | - T Hernández-Mojica
- Department of Genetics, National Institute of Neurology and Neurosurgery MVS, Insurgentes Sur 3877 Col, La Fama, Tlalpan 14269 CDMX, Mexico
| | - F Paz-Rodríguez
- Department of Neuropsychology, National Institute of Neurology and Neurosurgery MVS, Mexico
| | - A Jara-Prado
- Department of Genetics, National Institute of Neurology and Neurosurgery MVS, Insurgentes Sur 3877 Col, La Fama, Tlalpan 14269 CDMX, Mexico
| | | | - M A Sánchez-Guzmán
- Violence Research Laboratory, National Institute of Neurology and Neurosurgery MVS, Mexico
| | - J L Guerrero-Camacho
- Department of Genetics, National Institute of Neurology and Neurosurgery MVS, Insurgentes Sur 3877 Col, La Fama, Tlalpan 14269 CDMX, Mexico
| | - T Corona-Vázquez
- Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery MVS, Mexico
| | - J Flores
- Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery MVS, Mexico; ABC Neurological center, Mexico
| | - A Camacho-Molina
- Department of Genetics, National Institute of Neurology and Neurosurgery MVS, Insurgentes Sur 3877 Col, La Fama, Tlalpan 14269 CDMX, Mexico
| | - V Rivas-Alonso
- Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery MVS, Mexico
| | - D J Dávila-Ortiz de Montellano
- Department of Genetics, National Institute of Neurology and Neurosurgery MVS, Insurgentes Sur 3877 Col, La Fama, Tlalpan 14269 CDMX, Mexico.
| |
Collapse
|
21
|
Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK, Greenbaum CJ, Atkinson M, Baidal D, Battaglia M, Becker D, Bingley P, Bosi E, Buckner J, Clements M, Colman P, DiMeglio L, Gitelman S, Goland R, Gottlieb P, Herold K, Knip M, Krischer J, Lernmark A, Moore W, Moran A, Muir A, Palmer J, Peakman M, Philipson L, Raskin P, Redondo M, Rodriguez H, Russell W, Spain L, Schatz D, Sosenko J, Wentworth J, Wherrett D, Wilson D, Winter W, Ziegler A, Anderson M, Antinozzi P, Benoist C, Blum J, Bourcier K, Chase P, Clare-Salzler M, Clynes R, Eisenbarth G, Fathman C, Grave G, Hering B, Insel R, Kaufman F, Kay T, Leschek E, Mahon J, Marks J, Nanto-Salonen K, Nepom G, Orban T, Parkman R, Pescovitz M, Peyman J, Pugliese A, Roep B, Roncarolo M, Savage P, Simell O, Sherwin R, Siegelman M, Skyler J, Steck A, Thomas J, Trucco M, Wagner J, Krischer JP, Leschek E, Rafkin L, Bourcier K, Cowie C, Foulkes M, Insel R, Krause-Steinrauf H, Lachin JM, Malozowski S, Peyman J, Ridge J, Savage P, Skyler JS, Zafonte SJ, Rafkin L, Sosenko JM, Kenyon NS, Santiago I, Krischer JP, Bundy B, Abbondondolo M, Dixit S, Pasha M, King K, Adcock H, Atterberry L, Fox K, Englert N, Mauras J, Permuy K, Sikes T, Adams T, Berhe B, Guendling L, McLennan L, Paganessi C, Murphy M, Draznin M, Kamboj S, Sheppard V, Lewis L, Coates W, Amado D, Moore G, Babar J, Bedard D, Brenson-Hughes J, Cernich M, Clements R, Duprau S, Goodman L, Hester L, Huerta-Saenz A, Asif I, Karmazin T, Letjen S, Raman D, Morin W, Bestermann E, Morawski J, White A, Brockmyer R, Bays S, Campbell A, Boonstra M, Stapleton N, Stone A, Donoho H, Everett H, Hensley M, Johnson C, Marshall N, Skirvin P, Taylor R, Williams L, Burroughs C, Ray C, Wolverton D, Nickels C, Dothard P, Speiser M, Pellizzari L, Bokor K, Izuora S, Abdelnour P, Cummings S, Cuthbertson D, Paynor M, Leahy M, Riedl S, Shockley R, Saad T, Briones S, Casella C, Herz K, Walsh J, Greening F, Deemer M, Hay S, Hunt N, Sikotra L, Simons D, Karounos R, Oremus L, Dye L, Myers D, Ballard W, Miers R, Eberhard C, Sparks K, Thraikill K, Edwards J, Fowlkes S, Kemp A, Morales L, Holland L, Johnson P, Paul A, Ghatak K, Fiske S, Phelen H, Leyland T, Henderson D, Brenner E, Oppenheimer I, Mamkin C, Moniz C, Clarson M, Lovell A, Peters V, Ford J, Ruelas D, Borut D, Burt M, Jordan S, Castilla P, Flores M, Ruiz L, Hanson J, Green-Blair R, Sheridan K, Garmeson J, Wintergerst G, Pierce A, Omoruyi M, Foster S, Kingery A, Lunsford I, Cervantes T, Parker P, Price J, Urben I, Guillette H, Doughty H, Haydock V, Parker P, Bergman S, Duncum C, Rodda A, Perelman R, Calendo C, Barrera E, Arce-Nunez Y, Geyer S, Martinez M, De la Portilla I, Cardenas L, Garrido M, Villar R, Lorini E, Calandra G, D’Annuzio K, Perri N, Minuto C, Hays B, Rebora R, Callegari O, Ali J, Kramer B, Auble S, Cabrera P, Donohoue R, Fiallo-Scharer M, Hessner P, Wolfgram A, Henderson C, Kansra N, Bettin R, McCuller A, Miller S, Accacha J, Corrigan E, Fiore R, Levine T, Mahoney C, Polychronakos V, Henry M, Gagne H, Starkman M, Fox D, Chin F, Melchionne L, Silverman I, Marshall L, Cerracchio J, Cruz A, Viswanathan J, Heyman K, Wilson S, Chalew S, Valley S, Layburn A, Lala P, Clesi M, Genet G, Uwaifo A, Charron T, Allerton W, Hsiao B, Cefalu L, Melendez-Ramirez R, Richards C, Alleyn E, Gustafson M, Lizanna J, Wahlen S, Aleiwe M, Hansen H, Wahlen C, Karges C, Levy A, Bonaccorso R, Rapaport Y, Tomer D, Chia M, Goldis L, Iazzetti M, Klein C, Levister L, Waldman E, Keaton N, Wallach M, Regelmann Z, Antal M, Aranda C, Reynholds A, Vinik P, Barlow M, Bourcier M, Nevoret J, Couper S, Kinderman A, Beresford N, Thalagne H, Roper J, Gibbons J, Hill S, Balleaut C, Brennan J, Ellis-Gage L, Fear T, Gray L, Law P, Jones C, McNerney L, Pointer N, Price K, Few D, Tomlinson N, Leech D, Wake C, Owens M, Burns J, Leinbach A, Wotherspoon A, Murray K, Short G, Curry S, Kelsey J, Lawson J, Porter S, Stevens E, Thomson S, Winship L, Liu S, Wynn E, Wiltshire J, Krebs P, Cresswell H, Faherty C, Ross L, Denvir J, Drew T, Randell P, Mansell S, Lloyd J, Bell S, Butler Y, Hooton H, Navarra A, Roper G, Babington L, Crate H, Cripps A, Ledlie C, Moulds R, Malloy J, Norton B, Petrova O, Silkstone C, Smith K, Ghai M, Murray V, Viswanathan M, Henegan O, Kawadry J, Olson L, Maddox K, Patterson T, Ahmad B, Flores D, Domek S, Domek K, Copeland M, George J, Less T, Davis M, Short A, Martin J, Dwarakanathan P, O’Donnell B, Boerner L, Larson M, Phillips M, Rendell K, Larson C, Smith K, Zebrowski L, Kuechenmeister M, Miller J, Thevarayapillai M, Daniels H, Speer N, Forghani R, Quintana C, Reh A, Bhangoo P, Desrosiers L, Ireland T, Misla C, Milliot E, Torres S, Wells J, Villar M, Yu D, Berry D, Cook J, Soder A, Powell M, Ng M, Morrison Z, Moore M, Haslam M, Lawson B, Bradley J, Courtney C, Richardson C, Watson E, Keely D, DeCurtis M, Vaccarcello-Cruz Z, Torres K, Muller S, Sandberg H, Hsiang B, Joy D, McCormick A, Powell H, Jones J, Bell S, Hargadon S, Hudson M, Kummer S, Nguyen T, Sauder E, Sutton K, Gensel R, Aguirre-Castaneda V, Benavides, Lopez D, Hemp S, Allen J, Stear E, Davis T, O’Donnell R, Jones A, Roberts J, Dart N, Paramalingam L, Levitt Katz N, Chaudhary K, Murphy S, Willi B, Schwartzman C, Kapadia D, Roberts A, Larson D, McClellan G, Shaibai L, Kelley G, Villa C, Kelley R, Diamond M, Kabbani T, Dajani F, Hoekstra M, Sadler K, Magorno J, Holst V, Chauhan N, Wilson P, Bononi M, Sperl A, Millward M, Eaton L, Dean J, Olshan H, Stavros T, Renna C, Milliard, Brodksy L, Bacon J, Quintos L, Topor S, Bialo B, Bancroft A, Soto W, Lagarde H, Tamura R, Lockemer T, Vanderploeg M, Ibrahim M, Huie V, Sanchez R, Edelen R, Marchiando J, Palmer T, Repas M, Wasson P, Wood K, Auker J, Culbertson T, Kieffer D, Voorhees T, Borgwardt L, DeRaad K, Eckert E, Isaacson H, Kuhn A, Carroll M, Xu P, Schubert G, Francis S, Hagan T, Le M, Penn E, Wickham C, Leyva K, Rivera J, Padilla I, Rodriguez N, Young K, Jospe J, Czyzyk B, Johnson U, Nadgir N, Marlen G, Prakasam C, Rieger N, Glaser E, Heiser B, Harris C, Alies P, Foster H, Slater K, Wheeler D, Donaldson M, Murray D, Hale R, Tragus D, Word J, Lynch L, Pankratz W, Badias F, Rogers R, Newfield S, Holland M, Hashiguchi M, Gottschalk A, Philis-Tsimikas R, Rosal S, Franklin S, Guardado N, Bohannon M, Baker A, Garcia T, Aguinaldo J, Phan V, Barraza D, Cohen J, Pinsker U, Khan J, Wiley L, Jovanovic P, Misra M, Bassi M, Wright D, Cohen K, Huang M, Skiles S, Maxcy C, Pihoker K, Cochrane J, Fosse S, Kearns M, Klingsheim N, Beam C, Wright L, Viles H, Smith S, Heller M, Cunningham A, Daniels L, Zeiden J, Field R, Walker K, Griffin L, Boulware D, Bartholow C, Erickson J, Howard B, Krabbenhoft C, Sandman A, Vanveldhuizen J, Wurlger A, Zimmerman K, Hanisch L, Davis-Keppen A, Bounmananh L, Cotterill J, Kirby M, Harris A, Schmidt C, Kishiyama C, Flores J, Milton W, Martin C, Whysham A, Yerka T, Bream S, Freels J, Hassing J, Webster R, Green P, Carter J, Galloway D, Hoelzer S, Roberts S, Said P, Sullivan H, Freeman D, Allen E, Reiter E, Feinberg C, Johnson L, Newhook D, Hagerty N, White L, Levandoski J, Kyllo M, Johnson C, Gough J, Benoit P, Iyer F, Diamond H, Hosono S, Jackman L, Barette P, Jones I, Sills S, Bzdick J, Bulger R, Ginem J, Weinstock I, Douek R, Andrews G, Modgill G, Gyorffy L, Robin N, Vaidya S, Crouch K, O’Brien C, Thompson N, Granger M, Thorne J, Blumer J, Kalic L, Klepek J, Paulett B, Rosolowski J, Horner M, Watkins J, Casey K, Carpenter C, Michelle Kieffer MH, Burns J, Horton C, Pritchard D, Soetaert A, Wynne C, Chin O, Molina C, Patel R, Senguttuvan M, Wheeler O, Lane P, Furet C, Steuhm D, Jelley S, Goudeau L, Chalmers D, Greer C, Panagiotopoulos D, Metzger D, Nguyen M, Horowitz M, Linton C, Christiansen E, Glades C, Morimoto M, Macarewich R, Norman K, Patin C, Vargas A, Barbanica A, Yu P, Vaidyanathan W, Nallamshetty L, Osborne R, Mehra S, Kaster S, Neace J, Horner G, Reeves C, Cordrey L, Marrs T, Miller S, Dowshen D, Oduah V, Doyle S, Walker D, Catte H, Dean M, Drury-Brown B, Hackman M, Lee S, Malkani K, Cullen K, Johnson P, Parrimon Y, Hampton M, McCarrell C, Curtis E, Paul, Zambrano Y, Paulus K, Pilger J, Ramiro J, Luvon Ritzie AQ, Sharma A, Shor A, Song X, Terry A, Weinberger J, Wootten M, Lachin JM, Foulkes M, Harding P, Krause-Steinrauf H, McDonough S, McGee PF, Owens Hess K, Phoebus D, Quinlan S, Raiden E, Batts E, Buddy C, Kirpatrick K, Ramey M, Shultz A, Webb C, Romesco M, Fradkin J, Leschek E, Spain L, Savage P, Aas S, Blumberg E, Beck G, Brillon D, Gubitosi-Klug R, Laffel L, Vigersky R, Wallace D, Braun J, Lernmark A, Lo B, Mitchell H, Naji A, Nerup J, Orchard T, Steffes M, Tsiatis A, Veatch R, Zinman B, Loechelt B, Baden L, Green M, Weinberg A, Marcovina S, Palmer JP, Weinberg A, Yu L, Babu S, Winter W, Eisenbarth GS, Bingley P, Clynes R, DiMeglio L, Eisenbarth G, Hays B, Leschek E, Marks J, Matheson D, Rafkin L, Rodriguez H, Spain L, Wilson D, Redondo M, Gomez D, McDonald A, Pena S, Pietropaolo M, Shippy K, Batts E, Brown T, Buckner J, Dove A, Hammond M, Hefty D, Klein J, Kuhns K, Letlau M, Lord S, McCulloch-Olson M, Miller L, Nepom G, Odegard J, Ramey M, Sachter E, St. Marie M, Stickney K, VanBuecken D, Vellek B, Webber C, Allen L, Bollyk J, Hilderman N, Ismail H, Lamola S, Sanda S, Vendettuoli H, Tridgell D, Monzavi R, Bock M, Fisher L, Halvorson M, Jeandron D, Kim M, Wood J, Geffner M, Kaufman F, Parkman R, Salazar C, Goland R, Clynes R, Cook S, Freeby M, Pat Gallagher M, Gandica R, Greenberg E, Kurland A, Pollak S, Wolk A, Chan M, Koplimae L, Levine E, Smith K, Trast J, DiMeglio L, Blum J, Evans-Molina C, Hufferd R, Jagielo B, Kruse C, Patrick V, Rigby M, Spall M, Swinney K, Terrell J, Christner L, Ford L, Lynch S, Menendez M, Merrill P, Pescovitz M, Rodriguez H, Alleyn C, Baidal D, Fay S, Gaglia J, Resnick B, Szubowicz S, Weir G, Benjamin R, Conboy D, deManbey A, Jackson R, Jalahej H, Orban T, Ricker A, Wolfsdorf J, Zhang HH, Wilson D, Aye T, Baker B, Barahona K, Buckingham B, Esrey K, Esrey T, Fathman G, Snyder R, Aneja B, Chatav M, Espinoza O, Frank E, Liu J, Perry J, Pyle R, Rigby A, Riley K, Soto A, Gitelman S, Adi S, Anderson M, Berhel A, Breen K, Fraser K, Gerard-Gonzalez A, Jossan P, Lustig R, Moassesfar S, Mugg A, Ng D, Prahalod P, Rangel-Lugo M, Sanda S, Tarkoff J, Torok C, Wesch R, Aslan I, Buchanan J, Cordier J, Hamilton C, Hawkins L, Ho T, Jain A, Ko K, Lee T, Phelps S, Rosenthal S, Sahakitrungruang T, Stehl L, Taylor L, Wertz M, Wong J, Philipson L, Briars R, Devine N, Littlejohn E, Grant T, Gottlieb P, Klingensmith G, Steck A, Alkanani A, Bautista K, Bedoy R, Blau A, Burke B, Cory L, Dang M, Fitzgerald-Miller L, Fouts A, Gage V, Garg S, Gesauldo P, Gutin R, Hayes C, Hoffman M, Ketchum K, Logsden-Sackett N, Maahs D, Messer L, Meyers L, Michels A, Peacock S, Rewers M, Rodriguez P, Sepulbeda F, Sippl R, Steck A, Taki I, Tran BK, Tran T, Wadwa RP, Zeitler P, Barker J, Barry S, Birks L, Bomsburger L, Bookert T, Briggs L, Burdick P, Cabrera R, Chase P, Cobry E, Conley A, Cook G, Daniels J, DiDomenico D, Eckert J, Ehler A, Eisenbarth G, Fain P, Fiallo-Scharer R, Frank N, Goettle H, Haarhues M, Harris S, Horton L, Hutton J, Jeffrrey J, Jenison R, Jones K, Kastelic W, King MA, Lehr D, Lungaro J, Mason K, Maurer H, Nguyen L, Proto A, Realsen J, Schmitt K, Schwartz M, Skovgaard S, Smith J, Vanderwel B, Voelmle M, Wagner R, Wallace A, Walravens P, Weiner L, Westerhoff B, Westfall E, Widmer K, Wright H, Schatz D, Abraham A, Atkinson M, Cintron M, Clare-Salzler M, Ferguson J, Haller M, Hosford J, Mancini D, Rohrs H, Silverstein J, Thomas J, Winter W, Cole G, Cook R, Coy R, Hicks E, Lewis N, Marks J, Pugliese A, Blaschke C, Matheson D, Pugliese A, Sanders-Branca N, Ray Arce LA, Cisneros M, Sabbag S, Moran A, Gibson C, Fife B, Hering B, Kwong C, Leschyshyn J, Nathan B, Pappenfus B, Street A, Boes MA, Peterson Eck S, Finney L, Albright Fischer T, Martin A, Jacqueline Muzamhindo C, Rhodes M, Smith J, Wagner J, Wood B, Becker D, Delallo K, Diaz A, Elnyczky B, Libman I, Pasek B, Riley K, Trucco M, Copemen B, Gwynn D, Toledo F, Rodriguez H, Bollepalli S, Diamond F, Eyth E, Henson D, Lenz A, Shulman D, Raskin P, Adhikari S, Dickson B, Dunnigan E, Lingvay I, Pruneda L, Ramos-Roman M, Raskin P, Rhee C, Richard J, Siegelman M, Sturges D, Sumpter K, White P, Alford M, Arthur J, Aviles-Santa ML, Cordova E, Davis R, Fernandez S, Fordan S, Hardin T, Jacobs A, Kaloyanova P, Lukacova-Zib I, Mirfakhraee S, Mohan A, Noto H, Smith O, Torres N, Wherrett D, Balmer D, Eisel L, Kovalakovska R, Mehan M, Sultan F, Ahenkorah B, Cevallos J, Razack N, Jo Ricci M, Rhode A, Srikandarajah M, Steger R, Russell WE, Black M, Brendle F, Brown A, Moore D, Pittel E, Robertson A, Shannon A, Thomas JW, Herold K, Feldman L, Sherwin R, Tamborlane W, Weinzimer S, Toppari J, Kallio T, Kärkkäinen M, Mäntymäki E, Niininen T, Nurmi B, Rajala P, Romo M, Suomenrinne S, Näntö-Salonen K, Simell O, Simell T, Bosi E, Battaglia M, Bianconi E, Bonfanti R, Grogan P, Laurenzi A, Martinenghi S, Meschi F, Pastore M, Falqui L, Teresa Muscato M, Viscardi M, Bingley P, Castleden H, Farthing N, Loud S, Matthews C, McGhee J, Morgan A, Pollitt J, Elliot-Jones R, Wheaton C, Knip M, Siljander H, Suomalainen H, Colman P, Healy F, Mesfin S, Redl L, Wentworth J, Willis J, Farley M, Harrison L, Perry C, Williams F, Mayo A, Paxton J, Thompson V, Volin L, Fenton C, Carr L, Lemon E, Swank M, Luidens M, Salgam M, Sharma V, Schade D, King C, Carano R, Heiden J, Means N, Holman L, Thomas I, Madrigal D, Muth T, Martin C, Plunkett C, Ramm C, Auchus R, Lane W, Avots E, Buford M, Hale C, Hoyle J, Lane B, Muir A, Shuler S, Raviele N, Ivie E, Jenkins M, Lindsley K, Hansen I, Fadoju D, Felner E, Bode B, Hosey R, Sax J, Jefferies C, Mannering S, Prentis R, She J, Stachura M, Hopkins D, Williams J, Steed L, Asatapova E, Nunez S, Knight S, Dixon P, Ching J, Donner T, Longnecker S, Abel K, Arcara K, Blackman S, Clark L, Cooke D, Plotnick L, Levin P, Bromberger L, Klein K, Sadurska K, Allen C, Michaud D, Snodgrass H, Burghen G, Chatha S, Clark C, Silverberg J, Wittmer C, Gardner J, LeBoeuf C, Bell P, McGlore O, Tennet H, Alba N, Carroll M, Baert L, Beaton H, Cordell E, Haynes A, Reed C, Lichter K, McCarthy P, McCarthy S, Monchamp T, Roach J, Manies S, Gunville F, Marosok L, Nelson T, Ackerman K, Rudolph J, Stewart M, McCormick K, May S, Falls T, Barrett T, Dale K, Makusha L, McTernana C, Penny-Thomas K, Sullivan K, Narendran P, Robbie J, Smith D, Christensen R, Koehler B, Royal C, Arthur T, Houser H, Renaldi J, Watsen S, Wu P, Lyons L, House B, Yu J, Holt H, Nation M, Vickers C, Watling R, Heptulla R, Trast J, Agarwal C, Newell D, Katikaneni R, Gardner C, Del A, Rio A, Logan H, Collier C, Rishton G, Whalley A, Ali S, Ramtoola T, Quattrin L, Mastrandea A, House M, Ecker C, Huang C, Gougeon J, Ho D, Pacuad D, Dunger J, May C, O’Brien C, Acerini B, Salgin A, Thankamony R, Williams J, Buse G, Fuller M, Duclos J, Tricome H, Brown D, Pittard D, Bowlby A, Blue T, Headley S, Bendre K, Lewis K, Sutphin C, Soloranzo J, Puskaric H, Madison M, Rincon M, Carlucci R, Shridharani B, Rusk E, Tessman D, Huffman H, Abrams B, Biederman M, Jones V, Leathers W, Brickman P, Petrie D, Zimmerman J, Howard L, Miller R, Alemzadeh D, Mihailescu R, Melgozza-Walker N, Abdulla C, Boucher-Berry D, Ize-Ludlow R, Levy C, Swenson, Brousell N, Crimmins D, Edler T, Weis C, Schultz D, Rogers D, Latham C, Mawhorter C, Switzer W, Spencer P, Konstantnopoulus S, Broder J, Klein L, Knight L, Szadek G, Welnick B, Thompson R, Hoffman A, Revell J, Cherko K, Carter E, Gilson J, Haines G, Arthur B, Bowen W, Zipf P, Graves R, Lozano D, Seiple K, Spicer A, Chang J, Fregosi J, Harbinson C, Paulson S, Stalters P, Wright D, Zlock A, Freeth J, Victory H, Maheshwari A, Maheshwari T, Holmstrom J, Bueno R, Arguello J, Ahern L, Noreika V, Watson S, Hourse P, Breyer C, Kissel Y, Nicholson M, Pfeifer S, Almazan J, Bajaj M, Quinn K, Funk J, McCance E, Moreno R, Veintimilla A, Wells J, Cook S, Trunnel J, Henske S, Desai K, Frizelis F, Khan R, Sjoberg K, Allen P, Manning G, Hendry B, Taylor S, Jones W, Strader M, Bencomo T, Bailey L, Bedolla C, Roldan C, Moudiotis B, Vaidya C, Anning S, Bunce S, Estcourt E, Folland E, Gordon C, Harrill J, Ireland J, Piper L, Scaife K, Sutton S, Wilkins M, Costelloe J, Palmer L, Casas C, Miller M, Burgard C, Erickson J, Hallanger-Johnson P, Clark W, Taylor A, Lafferty S, Gillett C, Nolan M, Pathak L, Sondrol T, Hjelle S, Hafner J, Kotrba R, Hendrickson A, Cemeroglu T, Symington M, Daniel Y, Appiagyei-Dankah D, Postellon M, Racine L, Kleis K, Barnes S, Godwin H, McCullough K, Shaheen G, Buck L, Noel M, Warren S, Weber S, Parker I, Gillespie B, Nelson C, Frost J, Amrhein E, Moreland A, Hayes J, Peggram J, Aisenberg M, Riordan J, Zasa E, Cummings K, Scott T, Pinto A, Mokashi K, McAssey E, Helden P, Hammond L, Dinning S, Rahman S, Ray C, Dimicri S, Guppy H, Nielsen C, Vogel C, Ariza L, Morales Y, Chang R, Gabbay L, Ambrocio L, Manley R, Nemery W, Charlton P, Smith L, Kerr B, Steindel-Kopp M, Alamaguer D, Liljenquist G, Browning T, Coughenour M, Sulk E, Tsalikan M, Tansey J, Cabbage N. Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes. Diabetes Care 2019; 42:192-199. [PMID: 30061316 PMCID: PMC6341285 DOI: 10.2337/dc18-0288] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Accepted: 06/28/2018] [Indexed: 02/03/2023]
Abstract
OBJECTIVE There are variable reports of risk of concordance for progression to islet autoantibodies and type 1 diabetes in identical twins after one twin is diagnosed. We examined development of positive autoantibodies and type 1 diabetes and the effects of genetic factors and common environment on autoantibody positivity in identical twins, nonidentical twins, and full siblings. RESEARCH DESIGN AND METHODS Subjects from the TrialNet Pathway to Prevention Study (N = 48,026) were screened from 2004 to 2015 for islet autoantibodies (GAD antibody [GADA], insulinoma-associated antigen 2 [IA-2A], and autoantibodies against insulin [IAA]). Of these subjects, 17,226 (157 identical twins, 283 nonidentical twins, and 16,786 full siblings) were followed for autoantibody positivity or type 1 diabetes for a median of 2.1 years. RESULTS At screening, identical twins were more likely to have positive GADA, IA-2A, and IAA than nonidentical twins or full siblings (all P < 0.0001). Younger age, male sex, and genetic factors were significant factors for expression of IA-2A, IAA, one or more positive autoantibodies, and two or more positive autoantibodies (all P ≤ 0.03). Initially autoantibody-positive identical twins had a 69% risk of diabetes by 3 years compared with 1.5% for initially autoantibody-negative identical twins. In nonidentical twins, type 1 diabetes risk by 3 years was 72% for initially multiple autoantibody-positive, 13% for single autoantibody-positive, and 0% for initially autoantibody-negative nonidentical twins. Full siblings had a 3-year type 1 diabetes risk of 47% for multiple autoantibody-positive, 12% for single autoantibody-positive, and 0.5% for initially autoantibody-negative subjects. CONCLUSIONS Risk of type 1 diabetes at 3 years is high for initially multiple and single autoantibody-positive identical twins and multiple autoantibody-positive nonidentical twins. Genetic predisposition, age, and male sex are significant risk factors for development of positive autoantibodies in twins.
Collapse
Affiliation(s)
- Taylor M. Triolo
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO
| | - Alexandra Fouts
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO
| | - Laura Pyle
- Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO
| | - Liping Yu
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO
| | - Peter A. Gottlieb
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO
| | - Andrea K. Steck
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Rahmanian S, Chung K, Kokozian C, Knighten M, Flores J, Alcantara M. EDUCATING LATINO TERMINALLY-ILL PATIENTS USING SPANISH-LANGUAGE HOSPICE VIDEO: INCREASING HOSPICE ENROLLMENT. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- S Rahmanian
- University of California, Los Angeles (UCLA)
| | - K Chung
- California State University, Northridge
| | | | | | - J Flores
- California State University, Northridge
| | | |
Collapse
|
23
|
Moore-Medlin T, Asarkar A, Ma X, Flores J, Gu X, Nathan C. The Role of Human Papillomavirus and Epstein-Barr Virus Co-infection in Oropharyngeal Squamous Cell Tumor Differentiation. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2017.12.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
24
|
Rito Y, Flores J, Rivas V, Corona T. Poor prognosis factors in chronic relapsing inflammatory optic neuritis (CRION). J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Antonio-Luna E, Acosta-Castillo GI, Ortiz-Maldonado JF, Estrada-Galindo A, Corona T, Flores J. [Comparison of neuromyelitis optica spectra according to AQP4 antibody serostatus in a Mexican referral centre]. Rev Neurol 2017; 65:311-321. [PMID: 28929473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
INTRODUCTION Recent studies report that patients with neuromyelitis optica (NMO) or seropositive NMO spectra disorders display clinical characteristics that are different from those of patients who are seropositive for the aquaporin-4 (AQP4) antibody. AIM To analyse the clinical and paraclinical characteristics of patients with NMO according to their serum AQP4 status. PATIENTS AND METHODS We conducted a retrospective study of 100 patients with NMO who fulfilled the Wingerchuk criteria: 70 were positive for the AQP4 antibody and 30 were seronegative. RESULTS 70% of the subjects met the criteria for NMO, and 30% met criteria for NMO spectra disorders. The seropositive patients presented greater disability in the scores on the American Spinal Injury Association scale (ASIA) and the Expanded Disability Status Scale (p = 0.034 and 0.004, respectively) compared to seronegatives during the follow-up; in this same group there was greater visual involvement (p = 0.02), a higher number of relapses (p = 0.008) and a greater number of spinal segments involved (p = 0.003). CONCLUSION This study provides an overview of the clinical and paraclinical characteristics of patients with NMO according to the AQP4 antibody serostatus. Patients who are seropositive for the AQP4 antibody present greater clinical and imaging involvement.
Collapse
Affiliation(s)
- E Antonio-Luna
- Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico DF, Mexico
| | - G I Acosta-Castillo
- Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico DF, Mexico
| | - J F Ortiz-Maldonado
- Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico DF, Mexico
| | - A Estrada-Galindo
- Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico DF, Mexico
| | - T Corona
- Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico DF, Mexico
| | - J Flores
- Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico DF, Mexico
| |
Collapse
|
26
|
Otero JA, Monsivais G, Morales A, Gutiérrez L, Díaz-de-Anda A, Flores J. Further understanding of doorway states in elastic systems. J Acoust Soc Am 2017; 142:646. [PMID: 28863612 DOI: 10.1121/1.4996500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
In a previous work an elastic bar with a groove or notch that presents a doorway state was studied when the system was excited with 20 cycles of harmonic signals. The strength function had a Lorentzian width Γd = 1/πτd, where τd is the decay time of the prompt response. In the present paper, the doorway-state phenomenon is analyzed again for the same harmonic signals but for a very large number of cycles. The strength-function phenomenon is once more obtained, but now with a Lorentzian width Γ' which is larger than Γd. A qualitative and numerical explanation of this fact is given, leading therefore to further understanding of doorway states in elastic systems. The numerical results show a very good agreement with the values measured in the laboratory.
Collapse
Affiliation(s)
- J A Otero
- Tecnológico de Monterrey, Campus Estado de México, Atizapán de Zaragoza, 52926 Estado de México, Mexico
| | - G Monsivais
- Instituto de Física, Universidad Nacional Autónoma de México, P.O. Box 20-364, 01000 Ciudad de México, Mexico
| | - A Morales
- Instituto de Ciencias Físicas, Universidad Nacional Autónoma de México, P.O. Box 48-3, 62251 Cuernavaca, Morelos, Mexico
| | - L Gutiérrez
- Instituto de Ciencias Físicas, Universidad Nacional Autónoma de México, P.O. Box 48-3, 62251 Cuernavaca, Morelos, Mexico
| | - A Díaz-de-Anda
- Instituto de Física, Benemérita Universidad Autónoma de Puebla, P.O. Box J-48, 72570 Puebla, Puebla, Mexico
| | - J Flores
- Instituto de Física, Universidad Nacional Autónoma de México, P.O. Box 20-364, 01000 Ciudad de México, Mexico
| |
Collapse
|
27
|
Flores J, LeBlanc AC. [P3–054]: THE NLRP1‐CAPASE 1 INFLAMMATORY PATHWAY AS A POTENTIAL THERAPEUTIC TARGET AGAINST AGE‐DEPENDENT COGNITIVE IMPAIRMENT AND ALZHEIMER DISEASE. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.1264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Ponce-Bautista A, Valverde PL, Flores J, Zavala-Hurtado A, Vite F, López-Ortega G, Pérez-Hernández MA. Photosynthetically active radiation and carbon gain drives the southern orientation of Myrtillocactus geometrizans fruits. Plant Biol (Stuttg) 2017; 19:279-285. [PMID: 27943489 DOI: 10.1111/plb.12530] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Accepted: 12/06/2016] [Indexed: 06/06/2023]
Abstract
The equatorial orientation of reproductive structures is known in some columnar cacti from extratropical deserts. It has been hypothesised that photosynthetically active radiation (PAR) interception is the main reason for this orientation, because of its key effect on nocturnal CO2 uptake. However, there are no studies addressing both the effect of PAR and its consequence, carbon gain, on fruit orientation. Accordingly, we tested whether PAR and carbon gain could explain the southern fruit orientation of Myrtillocactus geometrizans, an inter-tropical columnar cactus. We studied three populations of M. geometrizans in Mexico. For each population, azimuth of fruits, total daily PAR, nocturnal acid accumulation (NAA) and fruit production were measured. The relationships between rib orientation and number of fruits, as well as total daily PAR, were evaluated using periodic regressions. The effect of total daily PAR and NAA on number of fruits was assessed using generalised linear models. During spring, mean fruit orientation had a south azimuth for three populations. Likewise, rib orientation had a significant effect on fruit production, with the south-facing ribs having the maximum number of fruits. Total daily PAR was highest in the south-facing ribs, at least for those in the northern and central populations. Furthermore, during spring, there was a significant positive effect of total daily PAR and NAA on fruit production. Our results provide strong evidence that the higher carbon gain in equatorial ribs, through a highest interception of PAR, would be the responsible factor for equatorial orientation of fruits in an inter-tropical columnar cactus.
Collapse
Affiliation(s)
- A Ponce-Bautista
- Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de México, México
- Departamento de Biología, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de México, México
| | - P L Valverde
- Departamento de Biología, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de México, México
| | - J Flores
- División de Ciencias Ambientales, Instituto Potosino de Investigación Científica y Tecnológica, San Luis Potosí, SLP, México
| | - A Zavala-Hurtado
- Departamento de Biología, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de México, México
| | - F Vite
- Departamento de Biología, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de México, México
| | - G López-Ortega
- Departamento de Biología, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de México, México
| | - M A Pérez-Hernández
- Departamento de Biología, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de México, México
| |
Collapse
|
29
|
Acharya B, Alexandre J, Baines S, Benes P, Bergmann B, Bernabéu J, Branzas H, Campbell M, Caramete L, Cecchini S, de Montigny M, De Roeck A, Ellis JR, Fairbairn M, Felea D, Flores J, Frank M, Frekers D, Garcia C, Hirt AM, Janecek J, Kalliokoski M, Katre A, Kim DW, Kinoshita K, Korzenev A, Lacarrère DH, Lee SC, Leroy C, Lionti A, Mamuzic J, Margiotta A, Mauri N, Mavromatos NE, Mermod P, Mitsou VA, Orava R, Parker B, Pasqualini L, Patrizii L, Păvălaş GE, Pinfold JL, Popa V, Pozzato M, Pospisil S, Rajantie A, Ruiz de Austri R, Sahnoun Z, Sakellariadou M, Sarkar S, Semenoff G, Shaa A, Sirri G, Sliwa K, Soluk R, Spurio M, Srivastava YN, Suk M, Swain J, Tenti M, Togo V, Tuszyński JA, Vento V, Vives O, Vykydal Z, Whyntie T, Widom A, Willems G, Yoon JH, Zgura IS. Search for Magnetic Monopoles with the MoEDAL Forward Trapping Detector in 13 TeV Proton-Proton Collisions at the LHC. Phys Rev Lett 2017; 118:061801. [PMID: 28234515 DOI: 10.1103/physrevlett.118.061801] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Indexed: 06/06/2023]
Abstract
MoEDAL is designed to identify new physics in the form of long-lived highly ionizing particles produced in high-energy LHC collisions. Its arrays of plastic nuclear-track detectors and aluminium trapping volumes provide two independent passive detection techniques. We present here the results of a first search for magnetic monopole production in 13 TeV proton-proton collisions using the trapping technique, extending a previous publication with 8 TeV data during LHC Run 1. A total of 222 kg of MoEDAL trapping detector samples was exposed in the forward region and analyzed by searching for induced persistent currents after passage through a superconducting magnetometer. Magnetic charges exceeding half the Dirac charge are excluded in all samples and limits are placed for the first time on the production of magnetic monopoles in 13 TeV pp collisions. The search probes mass ranges previously inaccessible to collider experiments for up to five times the Dirac charge.
Collapse
Affiliation(s)
- B Acharya
- Physics Department, Theoretical Particle Physics & Cosmology Group, King's College, London, United Kingdom
- International Centre for Theoretical Physics, Trieste, Italy
| | - J Alexandre
- Physics Department, Theoretical Particle Physics & Cosmology Group, King's College, London, United Kingdom
| | - S Baines
- Formerly at School of Physics and Astronomy, The University of Manchester, Manchester, United Kingdom
| | - P Benes
- IEAP, Czech Technical University in Prague, Prague, Czech Republic
| | - B Bergmann
- IEAP, Czech Technical University in Prague, Prague, Czech Republic
| | - J Bernabéu
- IFIC, Universitat de València, CSIC, Valencia, Spain
| | - H Branzas
- Institute of Space Science, Bucharest, Măgurele, Romania
| | - M Campbell
- Experimental Physics Department, CERN, Geneva, Switzerland
| | - L Caramete
- Institute of Space Science, Bucharest, Măgurele, Romania
| | - S Cecchini
- INFN, Section of Bologna, Bologna, Italy
| | - M de Montigny
- Physics Department, University of Alberta, Edmonton, Alberta, Canada
| | - A De Roeck
- Experimental Physics Department, CERN, Geneva, Switzerland
| | - J R Ellis
- Physics Department, Theoretical Particle Physics & Cosmology Group, King's College, London, United Kingdom
- Theoretical Physics Department, CERN, Geneva, Switzerland
| | - M Fairbairn
- Physics Department, Theoretical Particle Physics & Cosmology Group, King's College, London, United Kingdom
| | - D Felea
- Institute of Space Science, Bucharest, Măgurele, Romania
| | - J Flores
- Formerly at Department of Physics and Astronomy, Stony Brook University, New York, New York, USA
| | - M Frank
- Department of Physics, Concordia University, Montréal, Québec, Canada
| | - D Frekers
- Physics Department, University of Muenster, Muenster, Germany
| | - C Garcia
- IFIC, Universitat de València, CSIC, Valencia, Spain
| | - A M Hirt
- Department of Earth Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland
| | - J Janecek
- IEAP, Czech Technical University in Prague, Prague, Czech Republic
| | | | - A Katre
- Section de Physique, Université de Genève, Geneva, Switzerland
| | - D-W Kim
- Physics Department, Gangneung-Wonju National University, Gangneung, Republic of Korea
| | - K Kinoshita
- Physics Department, University of Cincinnati, Cincinnati, Ohio, USA
| | - A Korzenev
- Section de Physique, Université de Genève, Geneva, Switzerland
| | - D H Lacarrère
- Experimental Physics Department, CERN, Geneva, Switzerland
| | - S C Lee
- Physics Department, Gangneung-Wonju National University, Gangneung, Republic of Korea
| | - C Leroy
- Département de physique, Université de Montréal, Québec, Canada
| | - A Lionti
- Section de Physique, Université de Genève, Geneva, Switzerland
| | - J Mamuzic
- IFIC, Universitat de València, CSIC, Valencia, Spain
| | - A Margiotta
- INFN, Section of Bologna & Department of Physics & Astronomy, University of Bologna, Bologna, Italy
| | - N Mauri
- INFN, Section of Bologna, Bologna, Italy
| | - N E Mavromatos
- Physics Department, Theoretical Particle Physics & Cosmology Group, King's College, London, United Kingdom
| | - P Mermod
- Section de Physique, Université de Genève, Geneva, Switzerland
| | - V A Mitsou
- IFIC, Universitat de València, CSIC, Valencia, Spain
| | - R Orava
- Physics Department, University of Helsinki, Helsinki, Finland
| | - B Parker
- The Institute for Research in Schools, Canterbury, United Kingdom
| | - L Pasqualini
- INFN, Section of Bologna & Department of Physics & Astronomy, University of Bologna, Bologna, Italy
| | - L Patrizii
- INFN, Section of Bologna, Bologna, Italy
| | - G E Păvălaş
- Institute of Space Science, Bucharest, Măgurele, Romania
| | - J L Pinfold
- Physics Department, University of Alberta, Edmonton, Alberta, Canada
| | - V Popa
- Institute of Space Science, Bucharest, Măgurele, Romania
| | - M Pozzato
- INFN, Section of Bologna, Bologna, Italy
| | - S Pospisil
- IEAP, Czech Technical University in Prague, Prague, Czech Republic
| | - A Rajantie
- Department of Physics, Imperial College, London, United Kingdom
| | | | - Z Sahnoun
- INFN, Section of Bologna, Bologna, Italy
- Centre for Astronomy, Astrophysics and Geophysics, Algiers, Algeria
| | - M Sakellariadou
- Physics Department, Theoretical Particle Physics & Cosmology Group, King's College, London, United Kingdom
| | - S Sarkar
- Physics Department, Theoretical Particle Physics & Cosmology Group, King's College, London, United Kingdom
| | - G Semenoff
- Department of Physics, University of British Columbia, Vancouver, British Columbia, Canada
| | - A Shaa
- Formerly at Department of Physics and Applied Physics, Nanyang Technological University, Singapore, Singapore
| | - G Sirri
- INFN, Section of Bologna, Bologna, Italy
| | - K Sliwa
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts, USA
| | - R Soluk
- Physics Department, University of Alberta, Edmonton, Alberta, Canada
| | - M Spurio
- INFN, Section of Bologna & Department of Physics & Astronomy, University of Bologna, Bologna, Italy
| | - Y N Srivastava
- Physics Department, Northeastern University, Boston, Massachusetts, USA
| | - M Suk
- IEAP, Czech Technical University in Prague, Prague, Czech Republic
| | - J Swain
- Physics Department, Northeastern University, Boston, Massachusetts, USA
| | | | - V Togo
- INFN, Section of Bologna, Bologna, Italy
| | - J A Tuszyński
- Physics Department, University of Alberta, Edmonton, Alberta, Canada
| | - V Vento
- IFIC, Universitat de València, CSIC, Valencia, Spain
| | - O Vives
- IFIC, Universitat de València, CSIC, Valencia, Spain
| | - Z Vykydal
- IEAP, Czech Technical University in Prague, Prague, Czech Republic
| | - T Whyntie
- The Institute for Research in Schools, Canterbury, United Kingdom
- Queen Mary University of London, London, United Kingdom
| | - A Widom
- Physics Department, Northeastern University, Boston, Massachusetts, USA
| | - G Willems
- Physics Department, University of Muenster, Muenster, Germany
| | - J H Yoon
- Physics Department, Konkuk University, Seoul, Korea
| | - I S Zgura
- Institute of Space Science, Bucharest, Măgurele, Romania
| |
Collapse
|
30
|
Poveda E, Hernández-Quero J, Pérez-Elías MJ, Ribas MA, Martínez-Madrid OJ, Flores J, Navarro J, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestaran A, García F, Paredes R. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. HIV Med 2016; 18:482-489. [PMID: 28035758 DOI: 10.1111/hiv.12479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/19/2016] [Indexed: 12/28/2022]
Abstract
OBJECTIVES Maraviroc (MVC) is a suitable drug for aviraemic subjects on antiretroviral treatment (ART) developing toxicity. Its prescription requires prior tropism testing. It is unknown if proviral DNA genotypic tropism testing is reliable for guiding MVC initiation in aviraemic subjects, so this study was carried out to address this issue. METHODS PROTEST was a phase 4, prospective, single-arm clinical trial carried out in 24 HIV care centres in Spain. MVC-naïve HIV-1-infected patients with HIV-1 RNA < 50 copies/mL on stable ART during the previous 6 months who required an ART change because of toxicity and who had R5 HIV, as determined by proviral DNA genotypic tropism testing, initiated MVC with two nucleoside reverse transcriptase inhibitors (NRTIs) and were followed for 48 weeks. Virological failure was defined as two consecutive viral load measurements > 50 copies/mL. RESULTS Tropism results were available for 141 of 175 (80.6%) subjects screened: 60% had R5 and 85% of these (n = 74) were finally included in the study. Previous ART included protease inhibitors (PIs) in 62% of subjects, nonnucleoside reverse transcriptase inhibitors (NNRTIs) in 36%, and integrase inhibitors (INIs) in 2%. Main reasons for treatment change were dyslipidaemia (42%), gastrointestinal symptoms (22%) and liver toxicity (15%). MVC was given alongside tenofovir (TDF)/emtricitabine (FTC) (54%) and abacavir (ABC)/lamivudine (3TC) (40%) in most patients. Eighty-four per cent of patients maintained a viral load < 50 copies/mL to week 48, whereas 16% discontinued treatment: two withdrew informed consent, one had an R5 to X4 shift between screening and baseline, one was lost to follow-up, one developed an adverse event (rash), two died from non-study-related causes, and five developed protocol-defined virological failure. CONCLUSIONS Initiation of MVC plus two NRTIs in aviraemic subjects based on genotypic tropism testing of proviral HIV-1 DNA is associated with low rates of virological failure for up to 1 year.
Collapse
Affiliation(s)
- E Poveda
- Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain
| | | | | | - M A Ribas
- Hospital Son Espases, Palma de Mallorca, Spain
| | | | - J Flores
- Hospital Arnau de Vilanova, Valencia, Spain
| | - J Navarro
- Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - F Gutiérrez
- Hospital Universitario de Elche, Elche, Spain
| | | | - A Imaz
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - A Ocampo
- Hospital Xeral de Vigo, Vigo, Spain
| | - A Artero
- Hospital Universitario Dr. Peset, Valencia
| | - F Blanco
- Hospital Carlos III, Madrid, Spain
| | - E Bernal
- Hospital Reina Sofía, Murcia, Spain
| | - J Pasquau
- Hospital Virgen de la Nieves, Granada, Spain
| | | | - N Pérez
- Universitat Politécnica de Catalunya, Barcelona, Spain
| | - A Aiestaran
- Universitat Politécnica de Catalunya, Barcelona, Spain
| | - F García
- Hospital Universitario San Cecilio, Granada, Spain
| | - R Paredes
- HIV Unit and irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | | |
Collapse
|
31
|
Villanueva V, Garcés M, López-González FJ, Rodriguez-Osorio X, Toledo M, Salas-Puig J, González-Cuevas M, Campos D, Serratosa JM, González-Giráldez B, Mauri JA, Camacho JL, Suller A, Carreño M, Gómez JB, Montoya J, Rodríguez-Uranga J, Saiz-Diaz R, González-de la Aleja J, Castillo A, López-Trigo J, Poza JJ, Flores J, Querol R, Ojeda J, Giner P, Molins A, Esteve P, Baigesr JJ. Erratum to "Safety, efficacy and outcome-related factors of perampanel over 12months in a real-world setting: The FYDATA study" [Epilepsy Res. 126 (2016) 201-210]. Epilepsy Res 2016; 129:174-175. [PMID: 28017504 DOI: 10.1016/j.eplepsyres.2016.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- V Villanueva
- Hospital Universitario y Politécnico La Fe, Valencia, Spain.
| | - M Garcés
- Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | | | | | - M Toledo
- Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - J Salas-Puig
- Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | | | - D Campos
- Hospital Clínico Universitario, Valladolid, Spain
| | | | | | - J A Mauri
- Hospital Clínico Universitario, Zaragoza, Spain
| | - J L Camacho
- Hospital Clínico Universitario, Zaragoza, Spain
| | - A Suller
- Hospital Clínico Universitario, Zaragoza, Spain
| | - M Carreño
- Hospital Clinic Universitari, Barcelona, Spain
| | - J B Gómez
- Hospital Clinic Universitari, Barcelona, Spain
| | - J Montoya
- Hospital Lluis Alcanyis, Xátiva, Spain
| | | | - R Saiz-Diaz
- Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | - A Castillo
- Consorcio Hospital General Universitario, Valencia, Spain
| | - J López-Trigo
- Consorcio Hospital General Universitario, Valencia, Spain
| | - J J Poza
- Hospital Universitario Donosti, Spain
| | - J Flores
- Hospital Nuestra Sẽnora Candelaria, Tenerife, Spain
| | - R Querol
- Hospital Universitario Infanta Cristina, Badajoz, Spain
| | - J Ojeda
- Hospital Universitario Infanta Sofia, Madrid, Spain
| | - P Giner
- Hospital Universitario Dr Peset, Valencia, Spain
| | - A Molins
- Hospital Universitario Josep Trueta, Girona, Spain
| | - P Esteve
- Hospital Verge de la Cinta, Tortosa, Spain
| | - J J Baigesr
- Hospital Universitario y Politécnico La Fe, Valencia, Spain
| |
Collapse
|
32
|
Aguilar MS, Cosson C, Loureiro CL, Devesa M, Martínez J, Villegas L, Flores J, Ludert JE, Noyau BAD, Noya O, Liprandi F, Pujol FH. Prevalence of infection with hepatitis C virus in Venezuela, as assessed with an immuno-assay based on synthetic peptides. Annals of Tropical Medicine & Parasitology 2016. [DOI: 10.1080/00034983.2001.11813628] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
33
|
Villanueva V, Garcés M, López-González F, Rodriguez-Osorio X, Toledo M, Salas-Puig J, González-Cuevas M, Campos D, Serratosa J, González-Giráldez B, Mauri J, Camacho J, Suller A, Carreño M, Gómez J, Montoya J, Rodríguez-Uranga J, Saiz-Diaz R, González-de la Aleja J, Castillo A, López-Trigo J, Poza J, Flores J, Querol R, Ojeda J, Giner P, Molins A, Esteve P, Baiges J. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study. Epilepsy Res 2016; 126:201-10. [DOI: 10.1016/j.eplepsyres.2016.08.001] [Citation(s) in RCA: 80] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 07/18/2016] [Accepted: 08/03/2016] [Indexed: 01/05/2023]
|
34
|
|
35
|
Abstract
Two batches of dry-cured fermented sausage were made by industrial methods at pilot scale. The difference between them was the drying temperature applied (5 or 12 °C) for a period of time extending from the moment when pH = 5 was attained until a weight loss of 20% was achieved. The other conditions were the same for the two processes. Changes in pH, total acidity, D and L-lactic acids, acetic acid, total volatile basic nitrogen (TVBN), free amino acids (FAA) and free fatty acids (FFA) were studied, and a discriminatory sensory analysis of the ready-to-eat product was carried out. Only L-lactic acid and total acidity within the acidity parameters showed substantial differences halfway through the drying process. No significant differences were found in any of the acidity variables at the end of the process. The drying temperature encouraged the production of TVBN, but no direct relationship was established between it and the quantity of FAA. The three fractions of FFA [SFA (saturated fatty acids), MUFA (monounsaturated fatty acids) and PUFA (polyunsaturated fatty acids)] increased during the curing period, always higher at 12 °C than at 5 °C throughout the process. No differences between the two processes were detected by the discriminatory sensory analysis.
Collapse
Affiliation(s)
| | - P. Nieto
- Instituto de Agroquímica y Tecnología de Alimentos, CSIC, P.O. Box 73, 46100 Burjassot, Valencia, Spain
| | - J. Flores
- Instituto de Agroquímica y Tecnología de Alimentos, CSIC, P.O. Box 73, 46100 Burjassot, Valencia, Spain
| |
Collapse
|
36
|
Cuéllar-Rodríguez G, Jurado E, Flores J. Beetle diversity in fragmented thornscrub and isolated trees. BRAZ J BIOL 2016; 77:92-96. [PMID: 27382996 DOI: 10.1590/1519-6984.10615] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 09/30/2015] [Indexed: 11/21/2022] Open
Abstract
Due to land use change mainly for induced agriculture, Tamaulipan thornscrubin northeast Mexico has been cleared and transformed into small patches of vegetation as small as isolated trees surrounded by agricultural fields. In this study, we explored how tree isolation or growing inside a fragment of remnant vegetation influence diversity of coleopterans in two plant species (Prosopis laevigata (Humb. &Bonpl.exWilld.) M.C. Johnst. (mesquite) and Ebenopsis ebano (Berl.) Barneby (Texas ebony). We found 72 coleopteran morphospecies; fifteen occurred mainly in remnant fragments and ten mainly in isolated trees. There were more insects under isolated mesquites than under those immersed in remnant fragments, while in Texas ebony the highest beetle density for isolated trees coincided with periods of bean and maize in surrounding agriculture.
Collapse
Affiliation(s)
- G Cuéllar-Rodríguez
- Facultad de Ciencias Forestales, Universidad Autónoma de Nuevo León, Linares, NL, México
| | - E Jurado
- Facultad de Ciencias Forestales, Universidad Autónoma de Nuevo León, Linares, NL, México
| | - J Flores
- División de Ciencias Ambientales, Instituto Potosino de Investigación Científica y Tecnológica, San Luis Potosí, SLP, México
| |
Collapse
|
37
|
Affiliation(s)
- I Calvo
- Department of Animal Pathology II, Division of Surgery, Veterinary Teaching Hospital, Veterinary School, 28040 Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
38
|
Peng S, Ma Y, Flores J, Cornfeldt M, Mitrovic B, Eidelberg D, Doudet DJ. Modulation of Abnormal Metabolic Brain Networks by Experimental Therapies in a Nonhuman Primate Model of Parkinson Disease: An Application to Human Retinal Pigment Epithelial Cell Implantation. J Nucl Med 2016; 57:1591-1598. [PMID: 27056614 DOI: 10.2967/jnumed.115.161513] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 03/07/2016] [Indexed: 01/30/2023] Open
Abstract
Abnormal covariance pattern of regional metabolism associated with Parkinson disease (PD) is modulated by dopaminergic pharmacotherapy. Using high-resolution 18F-FDG PET and network analysis, we previously derived and validated a parkinsonism-related metabolic pattern (PRP) in nonhuman primate models of PD. It is currently not known whether this network is modulated by experimental therapeutics. In this study, we examined changes in network activity by striatal implantation of human levodopa-producing retinal pigment epithelial (hRPE) cells in parkinsonian macaques and evaluated the reproducibility of network activity in a small test-retest study. METHODS 18F-FDG PET scans were acquired in 8 healthy macaques and 8 macaques with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced bilateral nigrostriatal dopaminergic lesions after unilateral putaminal implantation of hRPE cells or sham surgery. PRP activity was measured prospectively in all animals and in a subset of test-retest animals using a network quantification approach. Network activity and regional metabolic values were compared on a hemispheric basis between animal groups and treatment conditions. RESULTS All individual macaques showed clinical improvement after hRPE cell implantation compared with the sham surgery. PRP activity was elevated in the untreated MPTP hemispheres relative to those of the normal controls (P < 0.00005) but was reduced (P < 0.05) in the hRPE-implanted hemispheres. The modulation observed in network activity was supported by concurrent local and remote changes in regional glucose metabolism. PRP activity remained unchanged in the untreated MPTP hemispheres versus the sham-operated hemispheres. PRP activity was also stable (P ≥ 0.29) and correlated (R2 ≥ 0.926; P < 0.00005) in the test-retest hemispheres. These findings were highly reproducible across several PRP topographies generated in multiple cohorts of parkinsonian and healthy macaques. CONCLUSION We have demonstrated long-term therapeutic effects of hRPE cell implantation in nonhuman primate models of PD. The implantation of such levodopa-producing cells can concurrently decrease the elevated metabolic network activity in parkinsonian brains on an individual basis. These results parallel the analogous findings reported in patients with PD undergoing levodopa therapy and other symptomatic interventions. With further validation in large samples, 18F-FDG PET imaging with network analysis may provide a viable biomarker for assessing treatment response in animal models of PD after experimental therapies.
Collapse
Affiliation(s)
- Shichun Peng
- Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, New York
| | - Yilong Ma
- Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, New York
| | - Joseph Flores
- Department of Neurology, University of British Columbia, Vancouver, British Columbia, Canada
| | | | | | - David Eidelberg
- Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, New York
| | - Doris J Doudet
- Department of Neurology, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
39
|
Membrive I, Reig A, Foro P, Rodriguez N, Sanz J, Ortiz A, Quera J, Fernandez-Velilla E, Pera O, Jimenez R, Becerra N, Flores J, Algara M. EP-2018: Treatment with high dose rate plesiotherapy and custom moulds in skin cancer. Long term results. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)33269-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
Villanueva V, Garces M, Gonzalez FJL, Rodriguez-Osorio X, Uranga JJR, López-Gomáriz E, Montoya J, Aldea JJP, Molins A, Saiz-Diaz R, Aleja JGDL, Mauri JA, Castillo A, Picho FJLT, Toledo M, Puig JS, Blance DC, Flores J. FYDATA STUDY: PERAMPANEL STUDY IN A REAL-LIFE SETTING. J Neurol Neurosurg Psychiatry 2015. [DOI: 10.1136/jnnp-2015-312379.55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
FYDATA is a multi-centre, retrospective, 1-year, observational study (inclusion criteria: written informed consent to review clinical charts; patients ≥12 years old; partial-onset seizure [POS] diagnosis; perampanel treatment according to clinical practice as add-on therapy; patients with ≥1 POS in year prior to starting perampanel). The source of data was patient clinical records collected by physicians. An interim analysis was performed at 3 months in 111 patients (mean age: 37.8 years; mean epilepsy duration: 24 years). Mean seizure number/month at onset was 19.3. At baseline, patients had tried a mean of 8.3 antiepileptic drugs (AEDs) and half were taking ≥3 concomitant AEDs. 31% of patients had a comorbid psychiatric condition. At 3 months, with a mean perampanel dose of 5.4 mg, 9% of patients were seizure-free and 44% were responders (≥50% reduction in seizure number). Adverse events were reported by 41.4% of patients; most frequent were irritability (13.5%), somnolence (10.8%) and dizziness (9.9%). Irritability and aggressiveness were more frequent if patients had a comorbid psychiatric condition – personality disorder/hyperactivity. Preliminary results at 3 months in refractory POS patients receiving adjunctive perampanel in a real-life setting showed a promising response. Study sponsors: Eisai Inc. Writing support: Choice Healthcare Solutions; funding, Eisai Ltd.
Collapse
|
41
|
Hernández O, Sotelo J, Martínez Palomo A, Flores J, Ordoñez G, Pineda B. Morphological analysis of varicella zoster virus-like particles in fibroblast cultures inoculated with CSF from patients with relapsing-remitting multiple sclerosis. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.1077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Becerra N, Jimenez R, Prieto M, Anton N, Llonch C, Lopez C, Flores J, Padilla L, Villanueva S, Quera J. EP-1644: Absorbed dose due to guide tube path in HDR Brachytherapy. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41636-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Kaushal V, Dye R, Pakavathkumar P, Foveau B, Flores J, Hyman B, Ghetti B, Koller BH, LeBlanc AC. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ 2015; 22:1676-86. [PMID: 25744023 DOI: 10.1038/cdd.2015.16] [Citation(s) in RCA: 207] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Revised: 01/27/2015] [Accepted: 01/29/2015] [Indexed: 12/13/2022] Open
Abstract
Neuronal active Caspase-6 (Casp6) is associated with Alzheimer disease (AD), cognitive impairment, and axonal degeneration. Caspase-1 (Casp1) can activate Casp6 but the expression and functionality of Casp1-activating inflammasomes has not been well-defined in human neurons. Here, we show that primary cultures of human CNS neurons expressed functional Nod-like receptor protein 1 (NLRP1), absent in melanoma 2, and ICE protease activating factor, but not the NLRP3, inflammasome receptor components. NLRP1 neutralizing antibodies in a cell-free system, and NLRP1 siRNAs in neurons hampered stress-induced Casp1 activation. NLRP1 and Casp1 siRNAs also abolished stress-induced Casp6 activation in neurons. The functionality of the NLRP1 inflammasome in serum-deprived neurons was also demonstrated by NLRP1 siRNA-mediated inhibition of speck formation of the apoptosis-associated speck-like protein containing a caspase recruitment domain conjugated to green fluorescent protein. These results indicated a novel stress-induced intraneuronal NLRP1/Casp1/Casp6 pathway. Lipopolysaccharide induced Casp1 and Casp6 activation in wild-type mice brain cortex, but not in that of Nlrp1(-/-) and Casp1(-/-) mice. NLRP1 immunopositive neurons were increased 25- to 30-fold in AD brains compared with non-AD brains. NLRP1 immunoreactivity in these neurons co-localized with Casp6 activity. Furthermore, the NLRP1/Casp1/Casp6 pathway increased amyloid beta peptide 42 ratio in serum-deprived neurons. Therefore, CNS human neurons express functional NLRP1 inflammasomes, which activate Casp1 and subsequently Casp6, thus revealing a fundamental mechanism linking intraneuronal inflammasome activation to Casp1-generated interleukin-1-β-mediated neuroinflammation and Casp6-mediated axonal degeneration.
Collapse
Affiliation(s)
- V Kaushal
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Ch. Cote Ste-Catherine, Montreal, QC H3T1E2, Canada.,Department of Neurology and Neurosurgery, McGill University, 3775 University St., Montreal, QC H3A 2B4, Canada
| | - R Dye
- Department of Genetics, 120 Mason Farm Road 5000 D, Genetic Medicine Building CB#7264 UNC-Chapel Hill, Chapel Hill, NC 27599-7264, USA
| | - P Pakavathkumar
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Ch. Cote Ste-Catherine, Montreal, QC H3T1E2, Canada.,Department of Neurology and Neurosurgery, McGill University, 3775 University St., Montreal, QC H3A 2B4, Canada
| | - B Foveau
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Ch. Cote Ste-Catherine, Montreal, QC H3T1E2, Canada.,Department of Neurology and Neurosurgery, McGill University, 3775 University St., Montreal, QC H3A 2B4, Canada
| | - J Flores
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Ch. Cote Ste-Catherine, Montreal, QC H3T1E2, Canada.,Department of Neurology and Neurosurgery, McGill University, 3775 University St., Montreal, QC H3A 2B4, Canada
| | - B Hyman
- Massachusetts General Hospital, Mass General Institute for Neurodegeneration, 114 16th Street, Charlestown, MA 2129, USA
| | - B Ghetti
- Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN 46202-5120, USA
| | - B H Koller
- Department of Genetics, 120 Mason Farm Road 5000 D, Genetic Medicine Building CB#7264 UNC-Chapel Hill, Chapel Hill, NC 27599-7264, USA
| | - A C LeBlanc
- Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Ch. Cote Ste-Catherine, Montreal, QC H3T1E2, Canada.,Department of Neurology and Neurosurgery, McGill University, 3775 University St., Montreal, QC H3A 2B4, Canada
| |
Collapse
|
44
|
Flores J, Rito Y, Torres G, Jung H, Treviño-Frenk I, Corona T. Hypothyroidism in multiple sclerosis patient during fingolimod treatment. J Neurol Sci 2015; 348:272-3. [PMID: 25491264 DOI: 10.1016/j.jns.2014.11.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2014] [Revised: 10/28/2014] [Accepted: 11/04/2014] [Indexed: 10/24/2022]
Affiliation(s)
- J Flores
- Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| | - Y Rito
- Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
| | - G Torres
- Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| | - H Jung
- Laboratory of Neuropharmacology, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| | - I Treviño-Frenk
- Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| | - T Corona
- Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| |
Collapse
|
45
|
Wick M, Meade J, Vaught T, Nehls M, Flores J, Kaufman J, Tolcher A, Rasco D, Patnaik A, Moskaluk C, Papadopoulos K. 97 Utilization of low passage adenoid cystic carcinoma PDX models to identify novel combination therapies. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70223-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
46
|
Mabileau G, Schwarzinger M, Flores J, Patrat C, Matheron S, Yazdanpanah Y. COL09-01 : Procréation chez les couples VIH séro-différents : TasP, PrEP ou AMP ? (ANRS 12008). Med Mal Infect 2014. [DOI: 10.1016/s0399-077x(14)70079-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
47
|
Podzamczer D, Imaz A, Perez I, Viciana P, Valencia E, Curto J, Martin T, Castano M, Rojas J, Espinosa N, Moreno V, Asensi V, Iribarren JA, Clotet B, Force L, Bachiller P, Knobel H, Lopez Bernaldo De Quiros JC, Blanco JR, Rozas N, Vergas J, Ocampo A, Camacho A, Flores J, Gomez-Sirvent JL. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients. J Antimicrob Chemother 2014; 69:2536-40. [DOI: 10.1093/jac/dku157] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Villanueva V, Serratosa JM, Guillamón E, Garcés M, Giráldez BG, Toledo M, Salas-Puig J, López González FJ, Flores J, Rodríguez-Uranga J, Castillo A, Mauri JA, Camacho JL, López-Gomáriz E, Giner P, Torres N, Palau J, Molins A. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res 2014; 108:1243-52. [PMID: 24908564 DOI: 10.1016/j.eplepsyres.2014.04.014] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2014] [Revised: 03/28/2014] [Accepted: 04/28/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) licensed as adjunctive therapy in adults with partial-onset or focal seizures. OBJECTIVE To evaluate in a clinical practice setting the long-term efficacy and safety of ESL in patients with focal seizures. METHODS ESLIBASE was a retrospective study that included all patients with focal seizures who started ESL between January 2010 and July 2012 at 12 hospitals. ESL was prescribed individually according to real-life practice. Efficacy and safety were evaluated over 1 year. Switching from carbamazepine (CBZ) and oxcarbazepine (OXC) was assessed. RESULTS Three hundred and twenty-seven patients were included; 78% of patients were taking ≥2 other AEDs at baseline. Most (87%) began ESL because of poor seizure control and 13% because of adverse events (AEs) with CBZ or OXC. After 1 year, 237 patients (72.4%) remained on ESL. At 3, 6 and 12 months, the responder rate was 46.3%, 57.9%, and 52.5%, and 21.0%, 28.0%, and 25.3% of patients were seizure free. The responder rate significantly increased when ESL was combined with a non-sodium channel-targeting drug (non-SC drug) (66.7%) versus an SC drug (47.7%; p<0.001). At 12 months, 40.7% of patients had ≥1 AE; AEs led to treatment discontinuation in 16.2%. Dizziness, nausea, and somnolence were the most common AEs. The tolerability profile improved in >50% of the patients who switched from CBZ or OXC to ESL because of AEs. CONCLUSIONS ESL was well tolerated and effective in a real-world setting over 1 year. Side-effect profile improved when OXC and CBZ recipients were switched to ESL.
Collapse
Affiliation(s)
- V Villanueva
- Hospital Universitario y Politécnico La Fe, Valencia, Spain.
| | - J M Serratosa
- Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - E Guillamón
- Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - M Garcés
- Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - B G Giráldez
- Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M Toledo
- Hospital Universitario Vall d́Hebron, Barcelona, Spain
| | - J Salas-Puig
- Hospital Universitario Vall d́Hebron, Barcelona, Spain
| | - F J López González
- Complejo Hospitalario Universitario Santiago, Santiago de Compostela, Spain
| | - J Flores
- Hospital Universitario Nuestra Señora Candelaria, Tenerife, Spain
| | - J Rodríguez-Uranga
- Instituto de Especialidades Neurológicas (IENSA), Clinica Sagrado Corazón, Sevilla, Spain
| | - A Castillo
- Consorcio Hospital General Universitario Valencia, Valencia, Spain
| | - J A Mauri
- Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - J L Camacho
- Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | | | - P Giner
- Hospital Universitario, Dr. Peset, Valencia, Spain
| | - N Torres
- Hospital Universitario, Dr. Peset, Valencia, Spain
| | - J Palau
- Hospital de Manises, Manises, Spain
| | - A Molins
- Hospital Universitario Dr. JosepTrueta, Girona, Spain
| |
Collapse
|
49
|
Flores J, Telles Esmeraldino AM, Ferreira Rodrigues R, Cruz LA, Mattos RC, Fiala Rechsteiner SM. Receptors for luteinizing hormone in different portions of the oviducts in estrus’ mares. PFERDEHEILKUNDE 2014. [DOI: 10.21836/pem20140106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
50
|
Díaz-de-Anda A, Flores J, Gutiérrez L, Méndez-Sánchez RA, Monsivais G, Morales A. Emergence of acoustic and optical bands in elastic systems. J Acoust Soc Am 2013; 134:4393. [PMID: 25669250 DOI: 10.1121/1.4828822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Two elastic systems are considered in this work: A special linear chain of harmonic oscillators and a quasi one-dimensional vibrating rod. Starting in both cases with a locally periodic system formed by unit cells with a single element, these cells are converted into binary cells. The acoustic and optical bands then appear. For the vibrating rod experimental values are compared with theoretical results; in particular, the normal-mode amplitudes are obtained and the agreement is excellent.
Collapse
Affiliation(s)
- A Díaz-de-Anda
- Instituto de Física, Universidad Nacional Autónoma de México, P.O. Box 20-364, 01000 México, Distrito Federal, Mexico
| | - J Flores
- Instituto de Física, Universidad Nacional Autónoma de México, P.O. Box 20-364, 01000 México, Distrito Federal, Mexico
| | - L Gutiérrez
- Instituto de Ciencias Físicas, Universidad Nacional Autónoma de México, P.O. Box 48-3, 62251 Cuernavaca, Mor., Mexico
| | - R A Méndez-Sánchez
- Instituto de Ciencias Físicas, Universidad Nacional Autónoma de México, P.O. Box 48-3, 62251 Cuernavaca, Mor., Mexico
| | - G Monsivais
- Instituto de Física, Universidad Nacional Autónoma de México, P.O. Box 20-364, 01000 México, Distrito Federal, Mexico
| | - A Morales
- Instituto de Ciencias Físicas, Universidad Nacional Autónoma de México, P.O. Box 48-3, 62251 Cuernavaca, Mor., Mexico
| |
Collapse
|